Hostname: page-component-7c8c6479df-fqc5m Total loading time: 0 Render date: 2024-03-18T01:02:02.212Z Has data issue: false hasContentIssue false

The Sir David Cuthbertson Medal Lecture Hunting for new pieces to the complex puzzle of obesity

The Annual Meeting of the Nutrition Society and the British Association for Parenteral and Enteral Nutrition was held at The International Centre, Telford on 16–17 November 2005

Published online by Cambridge University Press:  21 March 2007

Gema Frühbeck
Affiliation:
Department of Endocrinology and Metabolic Research Laboratory, Clínica Universitaria de Navarra, University of Navarra, 31008 – Pamplona, Spain
Rights & Permissions [Opens in a new window]

Abstract

Disentangling the neuroendocrine systems that regulate energy homeostasis and adiposity has been a long-standing challenge in pathophysiology, with obesity being an increasingly important public health problem. Adipose tissue is no longer considered a passive bystander in body-weight regulation. It actively secretes a large number of hormones, growth factors, enzymes, cytokines, complement factors and matrix proteins, at the same time as expressing receptors for most of these elements, which influence fuel storage, mobilisation and utilisation at both central and peripheral sites. Thus, an extensive cross talk at a local and systemic level in response to specific external stimuli or metabolic changes underpins the multifunctional characteristics of adipose tissue. In addition to the already-known adipokines, such as IL, TNFα, leptin, resistin and adiponectin, more recently attention has been devoted to ‘newcomers’ to the ‘adipose tissue arena’, which include aquaporin, caveolin, visfatin, serum amyloid A and vascular endothelial growth factor. While in vitro and in vivo experiments have provided extremely valuable information, the advances in genomics, proteomics and metabolomics are offering a level of information not previously attainable to help unlock the molecular basis of obesity. The potential and power of combining pathophysiological observations with the wealth of information provided by the human genome, knock-out models, transgenesis, DNA microarrays, RNA silencing and other emerging technologies offer a new and unprecedented view of a complex disease, conferring novel insights into old questions by identifying new pieces to the unfinished jigsaw puzzle of obesity.

Type
Research Article
Copyright
Copyright © The Nutrition Society 2006

Abbreviations:
AQP

aquaporin

GH

growth hormone

OB-R

leptin receptors

RYGB

proximal gastric bypass

SAA

serum amyloid A

SNAP

S-nitroso-N-acetyl-penicillamine

VEGF

vascular endothelial growth factor

VSMC

vascular smooth muscle cells

Over the last century nutrition science has evolved from an initial elucidation of the nutrients essential to life to a more sophisticated inquiry into how cells and systems work. Once the essential nutrients were identified, nutrition scientists started to uncover the metabolic pathways, gradually disentangling the detailed role of each nutrient in both physiological and pathological conditions. One of the more fascinating and rewarding aspects of nutrition is represented by the application of this huge body of knowledge to improve animal and human well-being. In particular, clinical nutrition aims to translate the scientific advances into changes in everyday practice. Sir David Cuthbertson carried out pioneering work in clinical metabolism, driving the knowledge concerning the catabolic response to injury and setting the basis for the therapeutic benefit of stress reduction after trauma. The currently-available technology is providing new impetus to further unravel the basic molecular mechanisms involved in metabolic processes and disease, fostering the progress made in clinical nutrition (Aitman, Reference Aitman2003; Müller & Kersten, Reference Müller and Kersten2003). In this context obesity represents an example worth considering in relation to the role of nutritional science (Trayhurn, Reference Trayhurn2005a).

During the last decade energy-balance control has been an extremely active and fruitful research topic (Flier, Reference Flier2004). Despite the unprecedented advances in the knowledge and understanding of systems biology, the obesity epidemic shows no signs of abatement (Fry & Finley, Reference Fry and Finley2005; Ogden et al. Reference Ogden, Carroll, Curtin, McDowell, Tabak and Flegal2006). The incidence of obesity and its main associated comorbidities, such as type 2 diabetes mellitus and CVD, has increased in the last decades, reaching epidemic proportions (Mokdad et al. Reference Mokdad, Ford, Bowman, Dietz, Vinicor, Bales and Marks2003; Gregg et al. Reference Gregg, Cheng, Cadwell, Imperatore, Williams, Flegal, Narayan and Williamson2005). Paradoxically, the perpetuation of the increases in the prevalences of overweight and obesity coincides with a scenario in which the preoccupation with body weight and diet pervades today's society. The hazards of excess body weight have been clearly established by epidemiological and clinical studies (Kopelman, Reference Kopelman2000; Calle et al. Reference Calle, Rodriguez, Walker-Thurmond and Thun2003; Fontaine et al. Reference Fontaine, Redden, Wang, Westfall and Allison2003; Frühbeck, Reference Frühbeck, Gibney, Elia, Ljungqvist and Dowsett2005a). Obesity will be among the leading causes of death and disability in the coming years, thus threatening to reverse many of the health gains achieved in the last decades (National Audit Office, 2001; Olshansky et al. Reference Olshansky, Passaro, Hershow, Layden, Carnes, Brody, Hayflick, Butler, Allison and Ludwig2005). Growing awareness of these risks has highlighted the need for increased insight into the understanding of the links between adipose tissue and pathophysiology.

The puzzle analogy

The neuroendocrine messages controlling energy storage and release have been a long-standing challenge in nutrition research for the last 50 years. From a simple point of view, body-weight maintenance results from the delicate balance between energy intake and expenditure. This balance, however, is subject to a plethora of multifactorial aspects ranging from genetic to environmental influences. Thus, the multidisciplinary nature of obesity represents the participation and interaction of many different elements that are intimately interconnected and can be viewed as the numerous pieces of a complex puzzle. Different strategies can be followed to solve a jigsaw puzzle. The pieces can be grouped according to different characteristics. For instance, sharing the same colour may help to identify pieces of the picture that probably fit together. Another approach is based on looking for pieces with a particular shape, which is very helpful to get the corners, edges and the ‘frame’ of the whole scene. The same is true for the complex puzzle of obesity. The current knowledge on this topic has been gathered from different perspectives. Valuable information has been derived from several approaches, such as whole-body physiology and in vitro and in vivo experiments, as well as from the observations of common obesity-associated conditions in both animals and man (Hetherington & Ranson, Reference Hetherington and Ranson1940; Frisch & McArthur, Reference Frisch and McArthur1974; Coleman, Reference Coleman1978; Bray & York, Reference Bray and York1979; Frühbeck, Reference Frühbeck2001; Frühbeck & Gómez-Ambrosi, Reference Frühbeck and Gómez-Ambrosi2001a; Trayhurn & Beattie, Reference Trayhurn and Beattie2001; Frayn et al. Reference Frayn, Karpe, Fielding, Macdonald and Coppack2003; Hauner, Reference Hauner2005). Extremely infrequent monogenic diseases (Farooqi & O'Rahilly, Reference Farooqi and O'Rahilly2005), as well as the completion of the human genome (Cummings & Schwartz, Reference Cummings and Schwartz2003; Bell et al. Reference Bell, Walley and Froguel2005; Clement, Reference Clement2005; Rankinen et al. Reference Rankinen, Zuberi, Chagnon, Weisnagel, Walts, Pérusse and Bouchard2006), have also contributed to achieving a more detailed insight. Furthermore, knocking out or overexpressing certain genes represents a further means of deciphering the importance of a specific protein or signalling cascade relevant to energy balance (Frühbeck & Gómez-Ambrosi, Reference Frühbeck and Gómez-Ambrosi2003; Blüher, Reference Blüher2005). The findings obtained from the wide range of the ‘omic’ technologies is providing an amount of information not previously attainable, with nutrigenomics (Müller & Kersten, Reference Müller and Kersten2003), epigenetics (Oommen et al. Reference Oommen, Griffin, Sarath and Zempleni2005), microarrays (Nadler & Attie, Reference Nadler and Attie2001; Collier et al. Reference Collier, Walder, De Silva, Tenne-Brown, Sanigorski, Segal, Kantham and Augert2002; Copland et al. Reference Copland, Davies, Shipley, Wood, Luxon and Urban2003; Middleton et al. Reference Middleton, Ramos, Xu, Diab, Zhao, Das and Meguid2004; Sjöholm et al. Reference Sjöholm, Palming, Olofsson, Gummesson, Svensson, Lystig, Jennische, Brandberg, Torgerson, Carlsson and Carlsson2005), in silico approaches (Borodina & Nielsen, Reference Borodina and Nielsen2005), RNA silencing (Ashrafi et al. Reference Ashrafi, Chang, Watts, Fraser, Kamath, Ahringer and Ruvkun2003; Grunweller & Hartmann, Reference Grunweller and Hartmann2005; Shankar et al. Reference Shankar, Manjunath and Lieberman2005) and other emerging technologies (Carella et al. Reference Carella, Volinia and Gasparini2003; Mobasheri et al. Reference Mobasheri, Airley, Foster, Schulze-Tanzil and Shakibaei2004; Droit et al. Reference Droit, Poirier and Hunter2005; Ruden et al. Reference Ruden, De Luca, Garfinkel, Bynum and Lu2005; Viguerie et al. Reference Viguerie, Poitou, Cancello, Stich, Clement and Langin2005) offering new and unprecedented tools in this area. Interestingly, all approaches can and should be combined to better understand the complex puzzle of obesity.

The author's work combines a clinical and whole-body physiology approach, together with the complementary information provided by molecular biology techniques, to the study of the pathophysiological mechanisms contributing to obesity and its associated comorbidities from the integrated perspective provided by everyday work in the clinical setting and basic research in experimental animals and cells. The efforts of the author's group are concentrated on three interconnected research lines (Fig. 1): (1) the impact of adiposity on the development of comorbidities; (2) the intracellular signalling pathways activated in adipocytes and vascular smooth muscle cells (VSMC); (3) adipose tissue gene expression profiling.

Fig. 1. Schematic representation of the selected research lines in obesity. (a), an image of a microarray; (b), a protein spectrum; VSMC, vascular smooth muscle cells; EC, endothelial cells.

Adipose tissue as an extremely-active endocrine–paracrine organ

Among the different functions of adipose tissue the findings have focused on its participation in lipolysis stimulation, blood pressure regulation and satiety control. White adipose tissue is no longer considered a passive bystander entirely devoted to energy storage. During the last decade adipose tissue has emerged as an active participant lying at the heart of a complex autocrine, paracrine and endocrine network that is implicated in the regulation of a variety of quite diverse pathophysiological functions, with its multifunctional nature being based on the ability of its cellular constituents to secrete a large number of products (Trayhurn, Reference Trayhurn2005b). These products can be categorised as hormones, growth factors, enzymes, cytokines, complement factors and matrix proteins, collectively termed adipokines; adipose tissue also expresses receptors for most of these factors (Trayhurn & Beattie, Reference Trayhurn and Beattie2001; Frühbeck & Salvador, Reference Frühbeck and Salvador2004; Trayhurn & Wood, Reference Trayhurn and Wood2004; Arner, Reference Arner2005a; Berg & Scherer, Reference Berg and Scherer2005; Yu & Ginsberg, Reference Yu and Ginsberg2005; Klein et al. Reference Klein, Perwitz, Kraus and Fasshauer2006). Adipose tissue is a special loose connective tissue that encompasses not only adipocytes but also other cell types (termed the stromavascular fraction), including blood cells, endothelial cells, macrophages and pericytes, as well as adipose precursor cells, which warrant an extensive cross talk at a local (Fig. 2) and systemic level in response to specific external stimuli or metabolic changes (Frühbeck & Gómez-Ambrosi, Reference Frühbeck, Gómez-Ambrosi, Caballero, Allen and Prentice2005). Glucocorticoids, sex steroids, PG, adipsin, leptin, resistin and adiponectin are now among the better known secretions of adipose tissue. Growth factors include insulin-like growth factor 1, macrophage colony-stimulating factor, transforming growth factor β, vascular endothelial growth factor (VEGF), heparin-binding epidermal growth factor, leukaemia inhibitory factor, nerve growth factor and bone morphogenetic protein. In the category of non-secreted factors, the prominent factors are perilipin, adiponutrin, adipophilin, uncoupling proteins and the membrane channel proteins GLUT-4, caveolins and aquaporin (AQP)-7. Special attention has been devoted to adipose-derived factors, which have been shown to be implicated either directly or indirectly in the regulation of vascular homeostasis through effects on blood pressure, inflammation, atherogenesis, coagulation, fibrinolysis, angiogenesis, proliferation, apoptosis and immunity (Frühbeck, Reference Frühbeck2004a; Fantuzzi, Reference Fantuzzi2005; Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005; Sjöholm & Nyström, Reference Sjöholm and Nyström2005; Permana et al. Reference Permana, Menge and Reaven2006). A key group is represented by proinflammatory–proliferative–prothrombotic–atherosclerotic–vascular factors such as TNFα, plasminogen activator inhibitor-1, tissue factor, angiotensinogen, metallothionein, C-reactive protein and IL (in particular IL-6, -1, -10 and -8). Interestingly, weight loss is associated with short-term beneficial effects on blood pressure, lipid metabolism, insulin sensitivity, susceptibility to thrombosis, inflammatory markers and sympathetic activity, which can be observed even with a modest 5–10% weight reduction (Frühbeck, Reference Frühbeck2004a). However, it has to be taken into consideration that in subjects with established risk factors for CVD and diabetes it is necessary to achieve initial weight losses of >10% in order to maintain longer-term losses of ≥5%, if the associated health benefits are the target (Krebs et al. Reference Krebs, Evans, Cooney, Mishra, Frühbeck, Finer and Jebb2002).

Fig. 2. Active cross talk between the numerous mediators secreted by the different cellular components of adipose tissue, which are enhanced in states of obesity, accompanied by recruitment of macrophages. Adipocytes and other cell types secrete inflammatory cytokines and immune factors exerting relevant autocrine, paracrine and endocrine influences. EC, endothelial cell; VSMC, vascular smooth muscle cell; MCP-1, monocyte chemoattractant protein-1; VEGF, vascular endothelial growth factor; C3, complement factor.

Regulation of lipid metabolism

In vertebrates adipose tissue represents the most important energy depot, which is stored in the form of triacylglycerols in a large lipid droplet that accounts for most of the adipocyte volume. Lipolysis of the stored triacylglycerols results in the release of glycerol and fatty acids from adipocytes and constitutes a key event in energy homeostasis (Arner, Reference Arner2005b). Fat cell lipolysis is subject to precise regulation by nutritional conditions, neuroendocrine influences and pathophysiological circumstances. A number of hormones, cytokines and enzymes control the lipolytic activity, with catecholamines and insulin being the most important elements regulating human fat cell lipolysis.

Participation of leptin in lipolysis

A decade ago the identification of functional leptin receptors (OB-R) in white adipose tissue suggested the involvement of leptin in the direct regulation of adipocyte metabolism at a peripheral level. In fact, leptin was shown to participate in lipid metabolism control through lipogenesis inhibition and lipolysis stimulation (Frühbeck, Reference Frühbeck2001). At a local level, leptin has the ability to repress acetyl-CoA carboxylase gene expression, fatty acid synthesis and lipid synthesis, which are biochemical reactions leading to lipid accumulation (Bai et al. Reference Bai, Zhang, Kim, Lee and Kim1996; Wang et al. Reference Wang, Lee and Unger1998). Additionally, leptin has been shown to exert an autocrine–paracrine lipolytic effect on white adipose tissue both in vitro and ex vivo (Frühbeck et al. Reference Frühbeck, Aguado and Martínez1997, Reference Frühbeck, Aguado, Gómez-Ambrosi and Martínez1998, Reference Frühbeck and Gómez-Ambrosi2001b; Wang et al. Reference Wang, Lee and Unger1998).

A functional relationship between leptin and NO has been established in several physiological processes (Frühbeck et al. Reference Frühbeck, Gómez-Ambrosi, Muruzábal and Burrell2001a; Frühbeck, Reference Frühbeck2006). Given the observed co-localisation of both factors in adipocytes and their involvement in lipolysis, the potential role of NO in the leptin-induced lipolytic effect has been investigated (Frühbeck & Gómez-Ambrosi, Reference Frühbeck and Gómez-Ambrosi2001b). A dose-dependent increase in both serum NO concentrations and basal adipose tissue lipolytic rate was observed 1 h after exogenous leptin administration, with simple linear regression analysis demonstrating that 27% of the variability taking place in lipolysis is attributable to the changes in NO concentrations. Inhibition of NO synthesis by using N ω-nitro-l-arginine methyl ester pretreatment was shown to be followed by a reduction in leptin-mediated lipolysis stimulation compared with leptin-treated control animals. In contrast, in adipocytes obtained from rats under acute ganglionic blockade by chlorisondamine administration it was found that the leptin-induced lipolytic effect is not different from the lipolytic rate achieved by leptin in control rats treated with saline (9 g NaCl/l; Fig. 3).

Fig. 3. Lipolysis under nitric oxide synthase (NOS) inhibition and acute ganglionic blockade. Wistar rats under pharmacological pretreatment consisting of intravenous administration of vehicle (saline (9 g sodium chloride/l); control group), NOS inhibition (N ωnitro-l-arginine methyl ester (L-NAME); 30 mg/kg) or acute ganglionic blockade (chlorisondamine; 30 mg/kg) were further injected with either saline (□) or leptin (100 mg/kg; ////) to study the effect on basal lipolysis of fat cells. The lipolytic activity was measured as the amount of glycerol released by isolated adipocytes after 1 h. Results are expressed as the percentage of basal lipolysis of fat cells from saline-treated control animals and are mean values with their standard errors represented by vertical bars for eight animals per group (lipolytic experiments were performed in duplicate). Mean values were significantly different from those for the saline-treated animals within the same pharmacological pretreatment group: **P<0·01, ***P<0·001. Mean values were significantly different from those for the control leptin-treated animals: †P<0·05. Statistical analyses were performed using ANOVA and post hoc pair-wise comparisons.

It is well known that a rise in cAMP as a result of either adenylate cyclase activation or phosphodiesterase inhibition stimulates lipolysis. In order to gain further insight into the potential mechanisms involved, lipolysis has been stimulated in isolated adipocytes using a number of agents acting at different levels of the lipolytic pathway (Fig. 4): (1) at the β-adrenergic receptor (isoproterenol); (2) at adenylate cyclase (forskolin); (3) at phosphodiesterase E (isobutylmethylxanthine); (4) at protein kinase A (dibutyryl-cAMP). In order to investigate the modulation of leptin-induced lipolysis by NO, the effect of S-nitroso-N-acetyl-penicillamine (SNAP), a known NO donor, was determined in vitro in adipocytes isolated from control rats and incubated with leptin, isoproterenol and combinations of the different lipolytic agents. The effect of OB-R deficiency on lipolysis activation was examined by further studying the effect of leptin, SNAP and catecholamines in fat cells of obese fa/fa rats. Leptin administration was found to have no significant effect on the lipolysis rate of white adipocytes derived from fa/fa rats (Frühbeck & Gómez-Ambrosi, Reference Frühbeck and Gómez-Ambrosi2001b). The addition of isoproterenol or SNAP to the incubation medium, however, was found to result in a marked lipolytic response, thus suggesting that adipocyte preparations obtained from fa/fa rats respond to other known lipolytic agents. When leptin and SNAP were present simultaneously in the incubation medium of adipocytes isolated from Wistar rats an additive effect on in vitro lipolysis was observed compared with the effect elicited by the products acting individually. Only the NO donor SNAP was able to exert a marked inhibitory effect on isoproterenol-stimulated lipolysis. It was further shown that leptin does not interfere with catecholamine-mediated lipolysis. On the other hand, it was shown that NO is a potentially relevant autocrine–paracrine physiological signal, regulating lipolysis by facilitating leptin-induced lipolysis and, at the same time, being capable of inhibiting catecholamine-induced lipolysis (Frühbeck & Gómez-Ambrosi, Reference Frühbeck and Gómez-Ambrosi2001b).

Fig. 4. Diagram of the site of action of diverse pharmacological agents at different levels of the lipolytic pathway. FSK, forskolin; AC, adenylate cyclase; Bt2-cAMP, dibutyryl-cAMP; HSL, hormone-sensitive lipase; PTX, pertussis toxin; Gi, inhibitory G-coupled protein; PKA, protein kinase A; CPA, N6-cyclopentyladenosine; ADA, adenosine deaminase; Adenos, adenosine; A1, adenosine receptor; PDE, phosphodiesterase E; P, phosphate; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; IBMX, isobutylmethylxanthine; , inhibitor; +, promoter.

Adenosine A1 receptors have been shown to be markedly expressed in adipocytes and influence fat cell metabolism via the regulation of adenylate cyclase, and therefore participate in lipolysis control via the inhibitory GTP-binding proteins (Honnor et al. Reference Honnor, Dhillon and Londos1985a,b). The adenosine deaminase gene had been previously shown to be linked to increased adiposity (LaNoue & Martin, Reference LaNoue and Martin1994; Bottini & Gloria-Bottini, Reference Bottini and Gloria-Bottini1999; Rankinen et al. Reference Rankinen, Zuberi, Chagnon, Weisnagel, Walts, Pérusse and Bouchard2006). The adenosinergic system reportedly increases leptin secretion by directly activating adenosine A1 in white adipose tissue (Rice et al. Reference Rice, Fain and Rivkees2000). Thus, the involvement of leptin in the transmembrane adenosinergic signalling system of adipocytes has been shown to be feasible from both a genetic and a biochemical and functional point of view. The results of these studies (Frühbeck et al. Reference Frühbeck, Gómez-Ambrosi and Salvador2001b) suggest a molecular mechanism that causes or maintains an increased adipose tissue mass, based on an altered functional regulation of lipolysis as a result of defective leptin-induced stimulation opposing the adenosine-mediated tonic inhibition. In fact, it has been shown (Frühbeck et al. Reference Frühbeck, Gómez-Ambrosi and Salvador2001b) that the lipolytic effect of leptin is located at the adenylate cyclase-inhibitory G proteins step, which provides an explanation for the defective stimulation of adipocyte adenylate cyclase and the blunted lipolysis observed in leptin-deficient rodents and in rodents lacking OB-R, as well as in morbidly-obese human subjects (Greenberg et al. Reference Greenberg, Taylor and Londos1987; Vannucci et al. Reference Vannucci, Klim, Martin and LaNoue1989; Martin et al. Reference Martin, Klim, Vannucci, Dixon, Landis and LaNoue1990).

Aquaporin-7

Recently, AQP7 has emerged as a new piece in the complex puzzle of obesity and insulin resistance. Over eons, mammalian evolution has selected for genes that allow for survival during famine or drought periods. The primary role of fat cells is to store triacylglycerols during periods of energy excess and to mobilise this reserve when expenditure exceeds intake. Among the complex mechanisms underlying energy balance control, AQP7 has emerged as a novel pathway critical to the modulation of lipid metabolism (Frühbeck Reference Frühbeck2005b; Frühbeck et al. Reference Frühbeck, Catalán, Gómez-Ambrosi and Rodríguez2006). AQP are a family of integral membrane proteins favouring water movement across cell membranes (King et al. Reference King, Kozono and Agre2004). AQP transport water, in some cases together with small molecules such as glycerol and other small solutes. The identification of AQP has allowed the recognition of the relevance of water channels for homeostatic control, and their true contribution to human health and disease has started to unfold (Verkman, Reference Verkman2005). AQP7 belongs to the subcategory termed aquaglyceroporins, which comprise channels known to permeabilise glycerol as well as water (King et al. Reference King, Kozono and Agre2004; Hara-Chikuma & Verkman, Reference Hara-Chikuma and Verkman2006). Originally named AQPap, this water–glycerol pore was cloned from human adipose tissue (Kuriyama et al. Reference Kuriyama, Kawamoto, Ishida, Ohno, Mita, Matsuzawa, Nishizawa, Matsubara and Okubo1997; Kishida et al. Reference Kishida, Shimomura, Kondo, Kuriyama, Makino and Nishizawa2001; Kondo et al. Reference Kondo, Shimomura, Kishida, Kuriyama, Makino and Nishizawa2002). AQP7 deficiency in adipocytes has been associated with adult-onset obesity in mice; thus, providing evidence that AQP7 functions as a glycerol channel in vivo whereby adipocyte glycerol permeability exerts a key role in the regulation of fat accumulation (Maeda et al. Reference Maeda, Funahashi, Nagasawa, Kishida, Kuriyama, Nakamura, Kihara, Shimomura and Matsuzawa2004; Hara-Chikuma et al. Reference Hara-Chikuma, Sohara, Rai, Ikawa, Okabe, Sasaki, Uchida and Verkman2005; Hibuse et al. Reference Hibuse, Maeda, Funahashi, Yamamoto, Nagasawa and Mizunoya2005; Wintour & Henry Reference Wintour and Henry2006). Fat cells of AQP7-knock-out mice exhibit an increase in glycerol kinase activity, which stimulates triacylglycerol synthesis, ultimately leading to adipocyte hypertrophy and subsequent development of obesity. The control exerted by AQP7 over the efflux of glycerol from fat cells further highlights its role in aged mice as a determinant of whole-body glucose homeostasis and insulin sensitivity (Hibuse et al. Reference Hibuse, Maeda, Funahashi, Yamamoto, Nagasawa and Mizunoya2005). Interestingly, the coordinated regulation of fat-specific AQP7 and liver-specific AQP9 may be key to determining glucose metabolism in physiology and insulin resistance (Kuriyama et al. Reference Kuriyama, Shimomura, Kishida, Kondo, Furuyama and Nishizawa2002). Furthermore, the expression of AQP7 in fat cells has been reported to be sensitive to nutritional and neuroendocrine factors (Fig. 5) such as fasting, insulin, TNFα, steroids, adrenergic agonists and PPARγ (Kishida et al. Reference Kishida, Shimomura, Kondo, Kuriyama, Makino and Nishizawa2001; Kondo et al. Reference Kondo, Shimomura, Kishida, Kuriyama, Makino and Nishizawa2002; Kuriyama et al. Reference Kuriyama, Shimomura, Kishida, Kondo, Furuyama and Nishizawa2002; MacDougald & Burant, Reference MacDougald and Burant2005).

Fig. 5. Schematic representation of the nutritional and neuroendocrine factors regulating aquaporin-7 (AQP7) expression in adipocytes.

The potential contribution of AQP7 to human obesity development has not been completely elucidated. The AQP7 gene, which resides in chromosome 9p13, has not been previously identified as a candidate gene for obesity (Ishibashi et al. Reference Ishibashi, Yamauchi, Kageyama, Saito-Ohara, Ikeuchi, Marumo and Sasaki1998; Kishida et al. Reference Kishida, Shimomura, Kondo, Kuriyama, Makino and Nishizawa2001; Rankinen et al. Reference Rankinen, Zuberi, Chagnon, Weisnagel, Walts, Pérusse and Bouchard2006). The loss of function associated with mutation of the AQP7 gene has been identified only in a single human subject who showed no signs of development of obesity or diabetes (Kondo et al. Reference Kondo, Shimomura, Kishida, Kuriyama, Makino and Nishizawa2002). The only observed alteration associated with the homozygous mutation is an impaired increase in plasma glycerol in response to exercise.

The extent, as well as the true influence, of aquaglyceroporins in human energy balance remains to be fully established. A microarray analysis (Sjöholm et al. Reference Sjöholm, Palming, Olofsson, Gummesson, Svensson, Lystig, Jennische, Brandberg, Torgerson, Carlsson and Carlsson2005) has shown increased AQP7 expression levels in the adipose tissue of obese women compared with obese men, while no differences were observed between the subcutaneous and omental depots. Elucidating the exact contribution of AQP7 and its role in the regulation of glycerol permeability, together with the potential impact on the current worldwide ‘diabesity’ epidemic, will provide a fertile area of research.

Caveolins

Caveolae are 50–100 nm flask-shaped cell-surface plasma-membrane invaginations implicated in a wide range of cellular functions such as endocytosis, cholesterol homeostasis and cell signalling control (Cohen et al. Reference Cohen, Hnasko, Schubert and Lisanti2004). The discovery of caveolin (Rothberg et al. Reference Rothberg, Heuser, Donzell, Ying, Glenney and Anderson1992; now termed caveolin-1) as a protein marker and main component of caveolae has provided more insight into the roles of these organelles. Caveolins are integral membrane proteins that serve as the structural elements of caveolae. They function as scaffolding as well as being capable of recruiting numerous signalling molecules to the plasma membrane lipid rafts and regulating their activity (Stan, Reference Stan2005; Parton et al. Reference Parton, Hanzal-Bayer and Hancock2006). Interestingly, caveolins are cholesterol-binding proteins with a unique hairpin topology that allows both the amino and carboxy terminals to face the cytoplasm (Fig. 6). Three different caveolin isoforms have been identified so far, exhibiting a unique tissue distribution pattern. While caveolin-3 is expressed in skeletal, cardiac and smooth muscle cells (Tang et al. Reference Tang, Scherer, Okamoto, Song, Chu, Kohtz, Nishimoto, Lodish and Lisanti1996), caveolin-1 is expressed in the majority of cells, excluding those of the muscular lineage, with expression being particularly high in adipocytes, fibroblasts and epithelial and endothelial cells (Parton et al. Reference Parton, Joggerst and Simons1994; Scherer et al. Reference Scherer, Lewis, Volonte, Engelman, Galbiati, Couet, Kohtz, van Donselaar, Peters and Lisanti1997). Expression of caveolin-2 most closely follows the distribution pattern of caveolin-1, although it has been recently shown that caveolin-2 is also found in cardiac myocytes (Rybin et al. Reference Rybin, Grabham, Elouardighi and Steinberg2003).

Fig. 6. Location of caveolin in the plasma membrane invaginations (or caveolae) and potential underlying mechanisms that lead ultimately to insulin resistance via insulin receptor (Ins-R) signalling defects.

The study of the phenotypes of caveolin-knock-out mice has considerably enhanced the understanding of the functional contribution of these proteins in diverse tissues and cellular processes (Le Lay & Kurzchalia, Reference Le Lay and Kurzchalia2005). An in vivo role for caveolin-1 in the development of obesity and insulin resistance through a direct participation in lipid homeostasis has been clearly established (Razani et al. Reference Razani, Combs, Wang, Frank, Park, Russell, Li, Tang, Jelicks, Scherer and Lisanti2002; Cohen et al. Reference Cohen, Combs, Scherer and Lisanti2003a,Reference Cohen, Hnasko, Schubert and Lisantib). Despite an evident hyperphagia, caveolin-1-knock-out mice show a lean phenotype with overt resistance to diet-induced obesity resulting from an impaired adipocyte functioning as a consequence of altered lipid handling. Adipocytes of caveolin-1-null mice lack caveolae, a derangement that with increasing age translates into a systemic inability for lipid accumulation, resulting in a near complete ablation of fat depots accompanied by histological alterations, including reduced fat cell number and diameter. The difference in weight of caveolin-1-knock-out mice when compared with wild-type mice becomes even more striking when the rodents are challenged with a high-fat diet. Caveolin-1-deficient mice show normal circulating glucose, insulin and cholesterol concentrations at the same time as exhibiting increased triacylglycerol and NEFA levels. The impaired triacylglycerol clearance takes place in the setting of normal total and hepatic lipoprotein lipase activity. It has further been shown that caveolin-1 is essential for adequate non-shivering thermogenesis in brown adipose tissue (Cohen et al. Reference Cohen, Schubert, Brasaemle, Scherer and Lisanti2005). Since caveolin-3 presents a high amino acid sequence homology to caveolin-1 (Song et al. Reference Song, Scherer, Tang, Okamoto, Li, Chu, Chafel, Chu, Kohtz and Lisanti1996), a role in energy balance and glucose homeostasis for this muscle-specific isoform could be expected. In contrast to the effect of caveolin-1 deficiency, in caveolin-3-knock-out mice there is an increased body weight at the expense of an elevated adiposity, accompanied by a normal food intake (Capozza et al. Reference Capozza, Combs, Cohen, Cho, Park and Schubert2005).

The relative importance of caveolins in insulin signalling in vivo has been investigated, as well as the clarification of the mechanisms that underlie potential tissue- or cell-specific signalling defects (Ishikawa et al. Reference Ishikawa, Otsu and Oshikawa2005). Caveolin-1-null mice exhibit a markedly decreased glucose uptake in response to an insulin tolerance test and develop postprandial hyperinsulinaemia when placed on a high-fat diet (Cohen et al. Reference Cohen, Razani, Wang, Combs, Williams, Scherer and Lisanti2003b). Since caveolin has been previously reported to operate as a positive regulator of insulin signalling (Yamamoto et al. Reference Yamamoto, Toya, Schwencke, Lisanti, Myers and Ishikawa1998), the involvement of caveolin-1 in this process has been examined. No changes in insulin receptor gene expression are evident in caveolin-1-deficient mice (Cohen et al. Reference Cohen, Razani, Wang, Combs, Williams, Scherer and Lisanti2003b). However, there is >90% reduction in insulin receptor protein levels in adipose tissue of these knock-out rodents, with ectopic expression of caveolin-1 being sufficient to restore expression to that of wild-type mice. The in vivo metabolic consequences of the genetic ablation of caveolin-3 in mice also affect glucose metabolism and lipid homeostasis, with caveolin-3-null mice displaying a marked postprandial hyperinsulinaemia and impaired glucose tolerance that progresses to whole-body insulin resistance with decreased insulin-stimulated whole-body glucose uptake. In particular, there is decreased glucose metabolic flux in skeletal muscle, as well as reduced insulin-mediated suppression of hepatic glucose production. Even in white adipose tissue, which does not express caveolin-3, an approximately 70% decrease in insulin-stimulated glucose uptake is observed that also suggests an insulin-resistant state for this tissue (Capozza et al. Reference Capozza, Combs, Cohen, Cho, Park and Schubert2005). Interestingly, caveolin-3-null mice have also been reported to develop whole-body insulin resistance associated with an impaired glucose tolerance (Oshikawa et al. Reference Oshikawa, Otsu, Toya, Tsunematsu, Hankins, Kawabe, Minamisawa, Umemura, Hagiwara and Ishikawa2004; Capozza et al. Reference Capozza, Combs, Cohen, Cho, Park and Schubert2005). Caveolae act as communication platforms, serving as a concentrating point for numerous signalling cascades. Effective insulin signalling in adipocytes is dependent on the localisation in caveolae of insulin-responsive elements. Caveolin-1 seems to play a role in the regulation of glucose homeostasis, both through a direct interaction with the insulin receptor and as an agent for GLUT4-mediated glucose uptake (Cohen et al. Reference Cohen, Combs, Scherer and Lisanti2003a). Caveolin-3 appears to attenuate the insulin-stimulated activation of insulin receptors and downstream molecules, such as insulin receptor substrate 1 and Akt, in skeletal muscles (Oshikawa et al. Reference Oshikawa, Otsu, Toya, Tsunematsu, Hankins, Kawabe, Minamisawa, Umemura, Hagiwara and Ishikawa2004; Capozza et al. Reference Capozza, Combs, Cohen, Cho, Park and Schubert2005).

Vasoactive factors secreted by adipose tissue

Mature adipocytes are characterised by the ability to synthesise a pleiad of proteins, which operate as relevant bioactive mediators. Recently, there has been particular interest in the vasoactive factors that exert an impact on the control of blood pressure, inflammation, atherogenesis, coagulation, fibrinolysis and angiogenesis (Wellen & Hotamisligil, Reference Wellen and Hotamisligil2003; Frühbeck, Reference Frühbeck2004a; Chaldakov et al. Reference Chaldakov, Tonchev, Georgieva, Ghenev and Stankulov2005; Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005; Trayhurn, Reference Trayhurn2005b; Matsuzawa, Reference Matsuzawa2006). The study of the effects of some adipokines, such as leptin, resistin, adiponectin, visfatin, ghrelin and other well-known cardiovascular risk factors, has provided a new insight into the molecular links between obesity and CVD.

Leptin

The role of leptin in the development of cardiovascular complications, beyond its effects on energy balance, only started to unfold some years after the identification of the hormone (Correia & Haynes, Reference Correia and Haynes2004; Matsuzawa, Reference Matsuzawa2005). Leptin has been shown to contribute to blood pressure homeostasis by inducing a pressor response attributable to sympathoactivation (Correia & Haynes, Reference Correia and Haynes2004) and a depressor response attributable to the vasodilation of conduit and resistance vessels (Frühbeck, Reference Frühbeck1999; Beltowski et al. Reference Beltowski, Wojcicka and Jamroz-Wisniewska2006; Beltowski, Reference Beltowski2006a). In relation to this role, the author's group was the first to identify NO as the key molecule responsible for the depressor response induced by leptin (Frühbeck, Reference Frühbeck1999). Subsequent studies have further shown that leptin acts on the endothelium, inducing the synthesis of NO via the activation of endothelial NO synthase, which induces an endothelium-dependent vasodilation (Kimura et al. Reference Kimura, Tsuda, Baba, Kawabe, Boh-oka, Ibata, Moriwaki, Hano and Nishio2000; Lembo et al. Reference Lembo, Vecchione, Fratta, Marino, Trimarco, d'Amati and Trimarco2000; Winters et al. Reference Winters, Mo, Brooks-Asplund, Kim, Shoukas, Li, Nyhan and Berkowitz2000; Beltowski et al. Reference Beltowski, Wójcicka and Borkowska2002; Vecchione et al. Reference Vecchione, Maffei, Colella, Aretini, Poulet, Frati, Gentile, Fratta, Trimarco, Trimarco and Lembo2002; Beltowski, Reference Beltowski2006a). Since OB-R are also expressed in the underlying smooth muscle layer, it is considered that VSMC also represent an important target for the vascular actions of leptin (Fortuño et al. Reference Fortuño, Rodríguez, Gómez-Ambrosi, Muñiz, Salvador, Díez and Frühbeck2002; Rodríguez et al. Reference Rodríguez, Frühbeck, Gómez-Ambrosi, Catalán, Sáinz, Díez, Zalba and Fortuño2006). It has been shown that leptin acts on VSMC, inhibiting the increase in cytosolic Ca induced by angiotensin II, thus blunting the contractile response caused by this potent vasoactive peptide. However, the intracellular mechanisms underlying this endothelium-independent vasodilation induced by leptin have not been completely elucidated. Given that the main signalling cascades activated by OB-R include the Janus kinase and signal transduction and activator of transcription cascades as well as the phosphoinositol-3 kinase/Akt pathways (Frühbeck, Reference Frühbeck2006; Peelman et al. Reference Peelman, Couturier, Dam, Zabeau, Tavernier and Jockers2006), it is hypothesised that an up-regulation of inducible NO synthase underlies the inhibitory effect of leptin on the angiotensin II-induced response in VSMC via the Janus kinase/signal transduction and activator of transcription and phosphoinositol-3 kinase/Akt pathways, as illustrated in Fig. 7.

Fig. 7. Diagram illustrating the nitric oxide-dependent intracellular pathways activated by leptin in arteries participating in blood pressure regulation. OB-R, leptin receptor; PI3K, phosphoinositol-3 kinase; JAK, Janus kinase; STAT, signal transduction and activator of transcription; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; Ang, angiotensin; ACE, angiotensin-converting enzyme; AT1-R, angiotensin receptor type 1; [Ca2+]i, cystolic calcium; , increase.

Leptin has been postulated to be one of the potential links between adiposity and inflammation (Berg & Scherer, Reference Berg and Scherer2005; Fantuzzi, Reference Fantuzzi2005; Härle & Straub, Reference Härle and Straub2006). Although the increase in the expression of leptin mRNA in white adipose tissue and the elevation in circulating concentrations triggered by inflammatory stimuli in experimental animals have not been consistently observed in human subjects (Fantuzzi & Faggioni, Reference Fantuzzi and Faggioni2000; Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Catalán, Diez-Caballero, Martínez-Cruz, Gil, García-Foncillas, Cienfuegos, Salvador, Mato and Frühbeck2004a), in general a proinflammatory role has been attributed to leptin. In this sense, the effects of leptin on inflammation and immunity need to be considered in a more broad and complex setting. In endothelial cells leptin has been shown to up regulate endothelin-1 and NO synthase, and stimulate the expression of adhesion molecules and monocyte chemoattractant protein-1, at the same time as inducing oxidative stress (Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005; Beltowski, Reference Beltowski2006b). Leptin has also been observed to stimulate angiogenesis, platelet aggregation and atherothrombosis, and to have a direct effect on macrophages, promoting their accumulation of cholesterol at the same time as leading to an increased release of monocyte colony-stimulating factor. Leptin operates as a chemoattractant devoid of secretagogue properties but capable of inhibiting neutrophil chemotaxis to classical neutrophilic chemoattractants (Montecucco et al. Reference Montecucco, Bianchi, Gnerre, Bertolotto, Dallegri and Ottonello2006). This effect is reportedly dependent on the activation of intracellular kinases and, in particular, via p38 mitogen-activated protein kinase and Src kinase (Montecucco et al. Reference Montecucco, Bianchi, Gnerre, Bertolotto, Dallegri and Ottonello2006).

Fibrinogen, C-reactive protein and von Willebrand factor represent well-known markers of inflammation and endothelial dysfunction, which are increased in obese patients (Hansson, Reference Hansson2005). A positive association has been observed between these markers and body fat, which in the case of fibrinogen and von Willebrand factor is higher than the correlation observed with BMI (Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Salvador, Páramo, Orbe, de Irala, Diez-Caballero, Gil, Cienfuegos and Frühbeck2002; Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Salvador, Silva, Pastor, Rotellar, Gil, Cienfuegos and Frühbeck2006b). Despite its wide use, BMI does not provide an accurate measure of body composition. In this context more precise indicators need to be incorporated into the clinical diagnosis of obesity in order to better estimate the cardiovascular-related risk (Frühbeck, Reference Frühbeck2004b). Although these markers are significantly correlated with leptin concentrations (P<0·001 for C-reactive protein; Fig. 8), the statistical significance is lost after adjusting for body fat, suggesting that they are not regulated by leptin itself. Recent studies (Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Salvador, Silva, Rotellar, Gil, Cienfuegos and Frühbeck2005, Reference Gómez-Ambrosi, Salvador, Silva, Pastor, Rotellar, Gil, Cienfuegos and Frühbeck2006b) have provided evidence of direct associations between adipose tissue stores and circulating concentrations of fibrinogen, C-reactive protein and von Willebrand factor that are not dependent on the influence of leptin.

Fig. 8. Scatter diagram showing the highly significant positive correlation (n 553; r 0·144; P<0·001) between the circulating concentrations of log leptin and log C-reactive protein (CRP). (●), Men; (△), women.

Resistin

The seminal observation of the induction of insulin resistance in mice by a novel adipokine led to it being termed resistin (Steppan et al. Reference Steppan, Bailey, Bhat, Brown, Banerjee, Wright, Patel, Ahima and Lazar2001). Increased circulating resistin concentrations have been observed in genetically-obese rodents (ob/ob and db/db mice) as well as in diet-induced obesity. Immunoneutralisation of resistin ameliorates hyperglycaemia and insulin resistance in these obese mice, while recombinant resistin administration results in impaired glucose tolerance and insulin action in normal mice (Steppan et al. Reference Steppan, Bailey, Bhat, Brown, Banerjee, Wright, Patel, Ahima and Lazar2001; Steppan & Lazar, Reference Steppan and Lazar2004). Glucose, growth hormone (GH), glucocorticoids, insulin, β3-adrenoreceptor stimulation and thiazolidinediones reportedly increase the expression of resistin (Koerner et al. Reference Koerner, Kratzsch and Kiess2005). However, insulin, TNFα, adrenaline, β-adrenergic receptor stimulation and thiazolidinediones have also been observed to decrease resistin gene expression (Steppan & Lazar, Reference Steppan and Lazar2004; Koerner et al. Reference Koerner, Kratzsch and Kiess2005). Moreover, the real contribution of resistin to human pathophysiology still remains controversial (Arner, Reference Arner2005a). Although resistin transcripts have been determined in adipose tissue of obese patients, no correlation between resistin mRNA levels and body weight, adiposity or insulin resistance has been observed (Gómez-Ambrosi & Frühbeck, Reference Frühbeck, Gibney, Elia, Ljungqvist and Dowsett2005a). The stromovascular fraction of adipose tissue and peripheral blood monocytes have been shown to express resistin. However, resistin mRNA is undetectable in human adipocytes of lean, insulin-resistant and obese patients and patients with diabetes (Koerner et al. Reference Koerner, Kratzsch and Kiess2005).

It has been established that resistin belongs to the RELM and FIZZ family of secreted proteins that have a tissue-specific pattern of expression and common signalling characteristics (Gómez-Ambrosi & Frühbeck, Reference Frühbeck2001). Indeed, resistin is identical to FIZZ3, while the amino acid sequence of RELMα is the same as that of FIZZ1, which had been previously shown to be overexpressed in allergic inflammation (Holcomb et al. Reference Holcomb, Kabakoff, Chan, Baker, Gurney and Henzel2000). Given that the pattern of expression and physiological functions described for these molecules resemble that of other well-known proinflammatory cytokines, and based on the superimposable expression pattern of FIZZ1/RELMα in inflammatory regions as well as cells, resistin has been proposed to be a critical mediator of the insulin resistance associated with sepsis and possibly other inflammatory settings (Gómez-Ambrosi & Frühbeck, Reference Frühbeck2001; Lehrke et al. Reference Lehrke, Reilly, Millington, Iqbal, Rader and Lazar2004).

Resistin has been shown to stimulate key processes in early atherosclerotic lesion formation, increasing the expression of monocyte chemoattractant protein-1 and cell adhesion molecules (vascular cell adhesion molecule-1 and intercellular adhesion molecule-1) in endothelial cells (Verma et al. Reference Verma, Li, Wang, Fedak, Li, Weisel and Mickle2003). In addition, resistin-treated cells have been reported to express lower TNFα receptor-associated factor, a potent inhibitor of CD40 ligand-mediated endothelial cell activation (Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005). Interestingly, the resistin-induced up-regulation of adhesion molecules is antagonised by adiponectin (Kawanami et al. Reference Kawanami, Maemura, Takeda, Harada, Nojiri, Imai, Manabe, Utsunomiya and Nagai2004). The involvement of resistin in endothelial dysfunction in patients who are insulin resistant has been attributed to its direct effect on endothelial cells by promoting the release of endothelin-1 (Gómez-Ambrosi & Frühbeck, Reference Frühbeck, Gibney, Elia, Ljungqvist and Dowsett2005a). It seems plausible that the proliferative effect of resistin on VSMC underlies the increased incidence of restenosis common among patients with diabetes (Gómez-Ambrosi & Frühbeck, Reference Frühbeck2005b).

Adiponectin

In pathological conditions such as obesity and the characteristic insulin resistance accompanying both the prediabetic state and overt type 2 diabetes mellitus, a clear hypoadiponectinaemia has been observed (Frühbeck & Salvador, Reference Frühbeck and Salvador2004; Arner, Reference Arner2005a; Berg & Scherer, Reference Berg and Scherer2005; Koerner et al. Reference Koerner, Kratzsch and Kiess2005). Adiponectin (also termed Acrp30, AdipoQ, apM1 or GBP28) operates completely differently from other known adipokines, since it has been shown to improve insulin sensitivity, inhibit vascular inflammation and exhibit a cardio-protective effect. White adipose tissue adiponectin expression has been observed to be increased in lean individuals and women, exhibiting an association with lower extents of insulin resistance and TNFα expression (Yamauchi et al. Reference Yamauchi, Kamon, Ito, Tsuchida, Yokomizo and Kita2003). Glucocorticoids, TNFα and IL-6 inhibit the gene expression of adiponectin in human visceral adipose tissue, while insulin, insulin-like growth factor 1 and PPARγ agonists increase its expression. To date three putative adiponectin receptors have been cloned. Adiponectin receptor 1 has been shown to be abundantly expressed in skeletal muscle and adiponectin receptor 2 is predominantly present in liver, while a third receptor has been identified in endothelial cells and smooth muscle (Kadowaki & Yamauchi, Reference Kadowaki and Yamauchi2005).

The cardio-protective characteristics of adiponectin have been attributed to its involvement in the prevention of atherosclerotic plaque formation through the inhibition of monocyte adhesion to endothelial cells, by decreasing NFκB signalling via a cAMP-dependent pathway (Ouchi et al. Reference Ouchi, Kihara, Arita, Okamoto, Maeda and Kuriyama2000; Kawanami et al. Reference Kawanami, Maemura, Takeda, Harada, Nojiri, Imai, Manabe, Utsunomiya and Nagai2004). Interestingly, in rodent models of atherosclerosis, such as ob/ob and apoE-deficient mice, adiponectin reportedly exerts a protective effect on the development of both atherosclerosis and type 2 diabetes mellitus (Frühbeck, Reference Frühbeck2004a; Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005). The findings in animals have a certain clinical parallel in human subjects, evidenced by a negative correlation between adiponectinaemia and markers of inflammation (Pischon et al. Reference Pischon, Girman, Hotamisligil, Rifai, Hu and Rimm2004; Xydakis et al. Reference Xydakis, Case, Jones, Hoogeveen, Liu, O'Brian, Nelson and Ballantyne2004). Circulating adiponectin levels have been observed to be inversely correlated with insulin resistance and C-reactive protein concentrations (Ouchi et al. Reference Ouchi, Kihara, Funahashi, Nakamura, Nishida and Kumada2003). In line with the cardio-protective properties of the adipokine, patients with CHD present with hypoadiponectinaemia compared with age- and BMI-adjusted controls, and a lower risk of myocardial infarction in men has been reported to be associated with high plasma adiponectin concentrations (Wellen & Hotamisligil, Reference Wellen and Hotamisligil2003). Furthermore, adiponectin has also been observed to regulate vascular inflammation via a direct effect on endothelial cells, as well as by decreasing VSMC proliferation and migration via a reduction in the effects of certain growth factors such as platelet-derived growth factor and heparin-binding epidermal growth factor (Frühbeck, Reference Frühbeck2004a). The detrimental effects of hypoadiponectinaemia in obesity, CVD and type 2 diabetes mellitus may be further related to an anti-inflammatory activity of the adipokine on macrophages. An inhibition of the endothelial inflammatory response by decreasing VSMC proliferation and vascular cell adhesion molecule-1 expression seems to underlie the anti-atherogenic effects of adiponectin (Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005).

Visfatin

Among the more recently identified adipokines, visfatin is mainly produced and secreted by visceral white adipose tissue. It has putative anti-diabetogenic properties through its binding to the insulin receptor and the exertion of an insulino-mimetic effect both in vitro and in vivo (Fukuhara et al. Reference Fukuhara, Matsuda, Nishizawa, Segawa, Tanaka and Kishimoto2005; Sethi & Vidal-Puig, Reference Sethi and Vidal-Puig2005). Originally identified as pre-B-cell colony-enhancing factor, visfatin is a cytokine that is abundantly present in the broncho-alveolar lavage fluid of animal models of acute lung injury as well as in the neutrophils of patients with sepsis (Fantuzzi, Reference Fantuzzi2005). In spite of the descriptive name, plasma concentrations of visfatin and visceral visfatin mRNA expression have been reported to correlate with measures of obesity but not with the visceral fat mass or the waist:hip ratio. Furthermore, no differences have been observed in visfatin mRNA expression between the visceral and subcutaneous fat depots (Berndt et al. Reference Berndt, Kloting, Kralisch, Kovacs, Fasshauer, Schon, Stumvoll and Bluher2005). IL-6 has been reported to exert an inhibitory effect on visfatin expression, which is in part mediated by the p44/42 mitogen-activated protein kinase (Kralisch et al. Reference Kralisch, Klein, Lossner, Bluher, Paschke, Stumvoll and Fasshauer2005). A 2-fold increase in circulating concentrations of visfatin has been observed in patients with type 2 diabetes mellitus (Chen et al. Reference Chen, Chung, Chang, Tsai, Huang, Shin and Lee2006). Nonetheless, after adjusting for BMI and waist:hip ratio the independent association between visfatin and diabetes disappears. The pathophysiological relevance of visfatin deserves further investigation in order to clarify the paradoxical effects of simultaneously favouring fat accretion and promoting insulin sensitivity (Arner, Reference Arner2006). It is still not clear whether visfatin actively participates in the feedback mechanisms regulating fat accretion in the intra-abdominal depot and its accompanying insulin resistance, or merely represents an epiphenomenon that might be useful as a surrogate marker of increased omental adipose tissue.

Vascular endothelial growth factor

Microarray technology has been applied to the analysis of gene expression profiles in adipose tissue obtained from lean and obese individuals in order to identify differential expression patterns and key genes involved in obesity. Consequently, attention has been focused on the changes observed in angiogenic factors (Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Catalán, Diez-Caballero, Martínez-Cruz, Gil, García-Foncillas, Cienfuegos, Salvador, Mato and Frühbeck2004b). VEGF is known to promote angiogenesis, inducing migration and proliferation of vascular endothelial cells (Berg & Scherer, Reference Berg and Scherer2005). Although VEGF is encoded by a single gene, four isoforms are produced by alternative splicing, which have been implicated in both normal blood vessel development and in pathogenic neovascularisation and atherosclerosis. In obese patients serum concentrations of one of the isoforms have been observed to be dependent on the intra-abdominal fat depot (Miyazawa-Hoshimoto et al. Reference Miyazawa-Hoshimoto, Takahashi, Bujo, Hashimoto and Saito2003). VEGF mRNA expression has been identified in various cell types, including endothelial, epithelial and mesenchymal cells. Interestingly, one of these microarray studies (Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Catalán, Diez-Caballero, Martínez-Cruz, Gil, García-Foncillas, Cienfuegos, Salvador, Mato and Frühbeck2004b) has provided evidence for increased expression of VEGF-B mRNA in omental adipose tissue of obese patients, in accordance with the need for enhanced vascularisation to support adipose mass enlargement. In particular, the mRNA of VEGF-B167 and VEGF-B186, the two known isoforms of VEGF-B, were shown to be up regulated 1·6-fold and 2·1-fold respectively. This finding suggests a potential link in the involvement of VEGF-B in angiogenesis and obesity-related endothelial dysfunction. This aspect needs to be explored further in relation to the implication that VEGF is involved in vascular inflammation and remodelling through increased subendothelial macrophage accumulation and intima media thickening in the context of atheroma initiation and restenosis episodes.

Serum amyloid A

Recognition of obesity as a chronic low-grade inflammatory state has driven recent productive research efforts. Adipose tissue is considered an extremely active immune organ that secretes numerous immunomodulatory factors, and it has emerged as an important source of inflammatory signals known to be related to comorbidity development (Trayhurn & Wood, Reference Trayhurn and Wood2004; Sjöholm & Nyström, Reference Sjöholm and Nyström2005). Thus, inflammation within white adipose tissue represents a crucial step, contributing to the appearance of many of the pathological features accompanying increased adiposity. The mounting evidence of the relevance of inflammation to vascular disease and insulin resistance has orientated plentiful research efforts towards molecules that modulate leucocyte migration from the bloodstream to the vessel wall. Serum amyloid A (SAA) is an acute-phase reactant protein secreted by diverse cell types, including adipocytes. It has been associated with systemic inflammation, as well as being linked to atherosclerosis and serving as a predictor for coronary disease and cardiovascular outcome (Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005). Circulating SAA concentrations are increased in obese patients and those with diabetes (Berg & Scherer, Reference Berg and Scherer2005). Under physiological circumstances white adipose tissue is known to express low levels of SAA, which have been shown to be strongly up regulated in obesity (Clément et al. Reference Clément, Viguerie, Poitou, Carette, Pelloux and Curat2004). From a mechanistic perspective, the detrimental effects of augmented SAA levels appear to be related to the displacement of apoA1 from HDL-cholesterol, increasing its binding to macrophages, therefore decreasing the availability of the cardio-protective HDL-cholesterol (Lau et al. Reference Lau, Dhillon, Yan, Szmitko and Verma2005). In addition, SAA functions as a chemoattractant, an inducer of remodelling metalloproteinases and a stimulator of T-cell cytokine production (Berg & Scherer, Reference Berg and Scherer2005).

A positive correlation between BMI and circulating SAA concentrations has been reported (Urieli-Shoval et al. Reference Urieli-Shoval, Linke and Matzner2000). However, whether serum SAA levels are increased in obese patients in relation to the body fat compartment was not directly addressed. In a recent study (Gómez-Ambrosi et al. Reference Gómez-Ambrosi, Salvador, Rotellar, Silva, Catalán, Rodríguez, Gil and Frühbeck2006a) obese patients were found to exhibit a 6-fold increase in circulating SAA concentrations compared with lean individuals. Furthermore, increased expression of SAA mRNA in the omental fat depot of obese patients was established. Interestingly, it was found that weight loss following bariatric surgery was able to reduce SAA concentrations, which may play a role, in part, in the beneficial effects that accompany weight reduction following bariatric surgery. It can be concluded that the elevated SAA levels in both serum and omental adipose tissue observed in obese patients may contribute to the obesity-associated CVD risk, which can be beneficially influenced by weight loss.

Ghrelin

Ghrelin is a potent GH-releasing peptide that was originally isolated from the stomach and subsequently identified as an endogenous ligand for the GH secretagogue receptor. It has been shown to be involved in the regulation of food intake by exerting an orexigenic effect (Kojima et al. Reference Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa1999; Inui et al. Reference Inui, Asakawa, Bowers, Mantovani, Laviano, Meguid and Fujimiya2004). Similarly to leptin, other sources of ghrelin production have been located, providing evidence for a physiological role of the hormone beyond energy balance (Ghigo et al. Reference Ghigo, Broglio, Arvat, Maccario, Papotti and Muccioli2005). The almost universal distribution of GH secretagogue receptors, including in adipose tissue and the cardiovascular system (Papotti et al. Reference Papotti, Ghe, Cassoni, Catapano, Deghenghi, Ghigo and Muccioli2000; Gnanapavan et al. Reference Gnanapavan, Kola, Bustin, Morris, McGee, Fairclough, Bhattacharya, Carpenter, Grossman and Korbonits2002), supports the plausibility of vascular actions of ghrelin (Cao et al. Reference Cao, Ong and Chen2006). In particular, GH secretagogue receptors are expressed in both blood vessels and cardiomyocytes, providing evidence for direct cardiovascular effects of ghrelin. Exogenous administration of ghrelin has been shown to exert beneficial haemodynamic effects via a vasodilatory effect, reducing mean arterial pressure and increasing cardiac index and stroke volume without elevating heart rate in human subjects and different rodent models (Cao et al. Reference Cao, Ong and Chen2006). Circulating ghrelin concentrations are reportedly decreased in obese individuals. Interestingly, ghrelin has been shown to induce vasorelaxation, acting via an endothelium-independent mechanism, which reverses the effect of endothelin-1 on isolated human arteries (Wiley & Davenport, Reference Wiley and Davenport2002), and at the same time exerts an effect on the endothelium by increasing endothelial NO bioavailability (Shimizu et al. Reference Shimizu, Nagaya, Teranishi, Imazu, Yamamoto, Shokawa, Kangawa, Kohno and Yoshizumi2003). Recent studies (Kawczynska-Drozdz et al. Reference Kawczynska-Drozdz, Olszanecki, Jawien, Brzozowski, Pawlik, Korbut and Guzik2006) have shown that ghrelin counteracts vascular oxidative stress through the inhibition of vascular superoxide production.

A direct cardio-protective effect of ghrelin has also been observed, with ghrelin operating as a trophic local factor to inhibit apoptosis of cardiomyocytes and endothelial cells in vitro through the activation of extracellular signal-regulated kinase-1/2 and Akt serine kinases (Baldanzi et al. Reference Baldanzi, Filigheddu, Cutrupi, Catapano, Bonissoni and Fubini2002). The signalling pathways underlying the vascular effects of ghrelin are being studied in more detail, extending to CD36, a multiligand scavenger receptor related to macrophage foam cell formation and the pathogenesis of atherosclerosis (Bodart et al. Reference Bodart, Febbraio, Demers, McNicoll, Pohankova, Perreault, Sejlitz, Escher, Silverstein, Lamontagne and Ong2002), as well as addressing the impact of the hormone on cell adhesion molecule expression (Skilton et al. Reference Skilton, Nakhla, Sieveking, Caterson and Celermajer2005). Taken together these findings highlight the involvement of ghrelin in the etiopathogenesis of hypertension as well as atherosclerosis.

Ghrelin changes following bariatric surgery

The last decade has witnessed major advances in the understanding of the basic metabolic pathways, brain circuitry, humoral responses and energy-consuming and -conserving processes, as well as psycho-social determinants of obesity (Horvath, Reference Horvath2005; Badman & Flier Reference Badman and Flier2005; Frühbeck, Reference Frühbeck2005c; Vaidya, Reference Vaidya2006). A sustained positive energy balance over a prolonged period of time, resulting from imbalances between food intake and energy expenditure, results in weight gain. The apparent simplicity of the laws of thermodynamics contrasts with the intricate mechanisms involved in guaranteeing energy homeostasis. In fact, appetite control is governed by a complex interaction of multiple processes, which include the participation of afferent signals from the gastrointestinal tract to provide information to the central nervous system.

In the current unabating overweight and obesity epidemic, bariatric surgery has been proven to be an effective therapeutic option for morbidly-obese carefully-selected patients with previous failure on conventional treatment (Buchwald et al. Reference Buchwald, Avidor, Braunwald, Jensen, Pories, Fahrbach and Schoelles2004; Steinbrook, Reference Steinbrook2004; Crookes, Reference Crookes2006; Hansen et al. Reference Hansen, Torquati and Abumrad2006; O'Brien et al. Reference O'Brien, Dixon, Laurie, Skinner, Proietto, McNeil, Strauss, Marks, Schachter, Chapman and Anderson2006). One of the effects of bariatric surgery is to enhance satiety and reduce subjective hunger. Adjustable gastric banding represents a purely restrictive intervention. It is primarily designed to decrease food intake through the placement of a silicone band around the upper part of the stomach to produce a pouch of reduced dimensions. Restrictive procedures increase oesophageal and gastric distension in response to small amounts of food, eliciting an early satiety sensation. The proximal gastric bypass (RYGB) and bilio-pancreatic diversion are both mixed techniques. They combine a restrictive effect derived from a small gastric reservoir and rapid transit via the gastrointestinal system with an added malabsorptive component resulting from undigested food being quickly shunted into the large intestine in the bilio-pancreatic diversion. Circulating ghrelin concentrations have been reported to be suppressed in morbidly-obese patients following RYGB (Cummings et al. Reference Cummings, Weigle, Frayo, Breen, Ma, Dellinger and Purnell2002), while no marked changes have been observed after adjustable gastric banding (Hanush-Enserer et al. Reference Hanush-Enserer, Brabant and Roden2003). This discrepancy has been attributed to the reduction in insulin secretion, which occurs as a result of improved insulin sensitivity and weight loss following adjustable gastric banding (Hanush-Enserer et al. Reference Hanush-Enserer, Brabant and Roden2003). However, the decrease in insulin resistance is even more evident in patients undergoing the RYGB. For this reason, the explanation of the discrepancies observed in circulating ghrelin concentrations after performing either a merely restrictive or a mixed procedure has been approached from a different perspective.

The isolation of ghrelin from the stomach represents a hallmark finding not only in the GH field, but also in appetite and energy balance control (Kojima et al. Reference Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa1999; Diéguez & Casanueva, Reference Diéguez and Casanueva2000; Inui et al. Reference Inui, Asakawa, Bowers, Mantovani, Laviano, Meguid and Fujimiya2004). In both animals and man the greatest amount of ghrelin-immunoreactivity has been found in neuroendocrine cells of the gastric fundus (Date et al. Reference Date, Kojima, Hosoda, Sawaguchi, Mondal, Suganuma, Matsukura, Kangawa and Nakazato2000; Tomasetto et al. Reference Tomasetto, Karam and Ribieras2000; Ariyasu et al. Reference Ariyasu, Takaya, Tagami, Ogawa, Hosoda and Akamizu2001; Gnanapavan et al. Reference Gnanapavan, Kola, Bustin, Morris, McGee, Fairclough, Bhattacharya, Carpenter, Grossman and Korbonits2002; Sakata et al. Reference Sakata, Nakamura, Yamazaki, Matsubara, Hayashi, Kangawa and Sakai2002). Most gastric ghrelin cells are closed-type cells that have no continuity with the lumen (Ariyasu et al. Reference Ariyasu, Takaya, Tagami, Ogawa, Hosoda and Akamizu2001), suggesting that they respond to physical stimuli from the lumen or chemical stimuli from the basolateral site, or both. As the most-frequently-performed bariatric surgery procedures are based on different mechanistic approaches in relation to the functional conservation of the fundus, it is hypothesised that the decrease in circulating ghrelin concentrations may depend on the impact of the selected surgical technique on the anatomy and physiology of the ghrelin-producing cells.

In order to avoid potential confounding influences, obese patients in the study of Frühbeck et al. (Reference Frühbeck, Diez-Caballero, Gil, Montero, Gómez-Ambrosi, Salvador and Cienfuegos2004a) were matched according to BMI, excess weight loss and percentage body fat. The study provides evidence that the abnormally-low ghrelin concentrations observed after RYGB do not only depend on surgically-induced weight loss, but on the extent of dysfunctionality of the fundus. Thus, the reduction in circulating ghrelin concentrations in patients undergoing diverse bariatric procedures depends on the extent to which the surgical technique excludes the fundus and the subsequent isolation of ghrelin-producing cells from direct contact with ingested nutrients, which regulate ghrelin concentrations. In agreement with this reasoning it has further been shown (Frühbeck et al. Reference Frühbeck, Diez-Caballero and Gil2004b) that the decrease in ghrelin concentrations in patients undergoing the RYGB takes place within 24 h after the surgical intervention, when potential confounding effects of weight loss and insulin sensitivity can be disregarded. A short-term dissociation of the leptin–insulin relationship in obese men following a bariatric intervention has previously been described (Frühbeck et al. Reference Frühbeck, Diez-Caballero, Gómez-Ambrosi, Gil, Monreal, Salvador and Cienfuegos2002).

A prospective study has addressed the reduction in circulating ghrelin concentrations in patients undergoing the RYGB at 6 months after surgery. The results indicate that ghrelin concentrations are not determined by an active weight loss or an improved insulin sensitivity, but rather depend on the surgically-induced bypass of the fundus (Frühbeck et al. Reference Frühbeck, Rotellar, Hernández-Lizoain, Gil, Gómez-Ambrosi, Salvador and Cienfuegos2004c). This observation is not in agreement with the findings of other studies with a longer follow-up period in which the initial reduction in circulating ghrelin concentrations attributable to the RYGB has not been observed (Faraj et al. Reference Faraj, Havel, Phélis, Blank, Sniderman and Cianflone2003). Plausible explanations for this controversial finding can be related to subtle differences in the surgical technique applied, which include the actual size of the stomach pouch remaining, whether or not a vagotomy was performed and the large interindividual variability in gastrointestinal hormones in response to nutritional challenges (Cummings & Shannon, Reference Cummings and Shannon2003; Morinigo et al. Reference Morinigo, Casamitjana, Moize, Lacy, Delgado, Gomis and Vidal2004; Jebb et al. Reference Jebb, Siervo, Frühbeck, Murgatroyd, Goldberg and Prentice2006). In order to gain an insight into the real contribution of ghrelin changes to body-weight reduction following RYGB, further long-term prospective studies are needed that address these issues and also consider potential individual compensatory mechanisms in relation to changes in the absorptive and secretory capacities of the remaining digestive tract. The differences in the extent to which bariatric surgery changes the anatomical and physiological conditions of the stomach, and the variations in the subsequent adaptive responses may contribute in the long term to the different average weight loss of excess body weight achieved by patients undergoing a RYGB.

Future perspectives

Nutrition pervades all branches of medicine (Allison, Reference Allison2005). An excess, a lack or even subtle imbalances of nutrients are among the causes of ill health. At the same time, diseases themselves can cause important nutritional and metabolic alterations. The wide spectrum ranging from a lack of nutrients to an excess of nutrients seamlessly embraces human development from intrauterine influences until death, exerting an undeniable effect on life expectancy. For this reason, nutritional care cannot be satisfactorily practised in isolation from other aspects of management and treatment, since drugs, fluid replacement, electrolyte balance and surgery affect nutritional status. Conversely, nutritional treatment exerts beneficial or detrimental effects according to its amount, composition and way of delivery and the pathophysiological circumstances in which it is given. The need to integrate healthy nutrition and lifestyles with the acquired knowledge and scientific background becomes especially important in halting the obesity pandemic.

Traditional boundaries among basic, clinical and patient-oriented research are merging into a single continuous bidirectional spectrum. In this spectrum studies involving basic science provide a physiological and molecular foundation for the development of novel experiments that lead to clinical investigations that synergistically open up new areas of knowledge and successful implementation (Fig. 9). However, despite the unprecedented molecular and technological advances, great concern about the obstacles encountered by translational research has recently been recognised (Hörig et al. Reference Hörig, Marincola and Marincola2005; Zerhouni, Reference Zerhouni2005). In this context, the obesity epidemic represents an example worth considering. During the last decade energy-balance control has been an extremely active and productive research topic. However, this increased knowledge has not translated into improved medical care of obesity or more effective prevention strategies, with childhood obesity deserving particular attention. On the contrary, a perpetuation of the increases in the prevalence of obesity parallels a scenario in which, paradoxically, opportunities for diagnosis and treatment appear to be missed (Galuska et al. Reference Galuska, Will, Serdula and Ford1999; Frühbeck et al. Reference Frühbeck, Diez-Caballero, Gómez-Ambrosi, Cienfuegos and Salvador2003). The final aim of alleviating human suffering will remain elusive as long as scientific advances fail to drive changes in everyday clinical practice fostered by a robust, bidirectional information flow between healthcare professionals and research scientists.

‘Knowing is not enough – we must apply; willing is not enough – we must do’

Johann Wolfgang von Goethe

Fig. 9. Clinical, patient-oriented and basic research merge into a single continuous bidirectional spectrum synergistically opening up new areas of knowledge and successful implementation.

Concluding remarks

Obesity research is like a dynamic puzzle; as more pieces of the puzzle are found, more questions arise and more pieces are needed. Some of the many pieces of the complex ‘obesity puzzle’ have been already identified and put together to explain some of the underlying mechanisms of adipose tissue regulation. However, energy homeostasis is a particularly active research topic. Barely 1 week passes without the spotlight falling on some new potential regulator of appetite or body weight. Most probably, certain pieces may have been misplaced, forced to fit where they do not really belong, thereby providing a distorted view or sometimes contradictory findings, as may be the case with resistin. It may also be necessary to change certain facets of an already known molecule so that it actually adapts to the surrounding space and forms of other related pieces (Fig. 10). Certainly, missing pieces that complete the complex puzzle still need to be found. Despite the growing understanding of adipose tissue biology, critical pathways have yet to be identified. Given its versatile and pleiotropic nature, additional and unexpected roles of adipose tissue are bound to emerge. In this sense, it is important to maintain an integral view, provided by complementary approaches with an open-minded and functional perspective. The inscription Sir David Cuthbertson chose for his coat of arms on receiving his knighthood in 1965 was ‘Understand and nourish’. ‘Understand’ represents the goal of science and ‘nourish’ stands for the importance of nutrition. This combination represents the exciting challenge in which researchers are taking part, trying to follow Sir David Cuthbertson's noble motto.

Fig. 10. Trying to fit the numerous pieces of the complex puzzle of obesity. SHIP2, type-II SH2-domain-containing inositol 5′-phosphatase; FABP, fatty acid-binding protein; SREBP-1, sterol regulatory element-binding protein 1; Sirt 1, sirtuin 1; elF4E, eukaryotic initiation factor 4E; FOX, Forkhead box protein (a transcription factor); carboxypep E, carboxypeptidase E; lysophospholip D, lysophospholipid D; TGF, transforming growth factor; HSL, hormone-sensitive lipase; VEGF, vascular endothelial growth factor; HIF-1, hypoxia-inducible factor-1; CGRP, calcitonin gene-related peptide; SAA, serum amyloid A.

Acknowledgements

I would like to express my personal thanks to all those colleagues who have made my work possible. Special thanks go to all the members of ‘my lab’, the Metabolic Research Laboratory, my colleagues from the Clínica Universitaria de Navarra, where we have a multidisciplinary obesity team, and to the patients. I am also grateful to my first hospital directors, Amador Sosa and Javier A. Cienfuegos, who many years ago had the vision to support the development of obesity treatment and research. The postdoctoral stay at the MRC Dunn Clinical Nutrition Centre in Cambridge in Professor Andrew Prentice's group had an indelible influence on my research career, providing an unsurpassable scientific and personal environment. Professor Prentice and his collaborators, Susan Jebb, Peter Murgatroyd and Gail Goldberg, were an endless source of inspiration and knowledge. Finally, I recognise that the wide range of difficulties that have challenged me have stimulated my endurance and creativity.

The financial support of the Spanish Plan Nacional de I+D+I of the Ministerio de Ciencia y Tecnología (SAF2003–09225), the FIS of the Instituto de Salud Carlos III, Red de Grupos RGTO (G03/028), the Department of Health of the Gobierno de Navarra (20/2005) and the PIUNA Foundation is greatfully acknowledged.

References

Aitman, TJ (2003) Genetic medicine and obesity. New England Journal of Medicine 348, 21382139.Google Scholar
Allison, SP (2005) Integrated nutrition. Proceedings of the Nutrition Society 64, 319323.Google Scholar
Ariyasu, H, Takaya, K, Tagami, T, Ogawa, Y, Hosoda, K, Akamizu, Tet al. (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. Journal of Clinical Endocrinology and Metabolism 86, 47534758.Google Scholar
Arner, P (2005a) Insulin resistance in type 2 diabetes – role of the adipokines. Current Molecular Medicine 5, 333339.Google Scholar
Arner, P (2005b) Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Practice and Research in Clinical Endocrinology and Metabolism 19, 471482.Google Scholar
Arner, P (2006) Visfatin – a true or false trail to type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 91, 2830.Google Scholar
Ashrafi, K, Chang, FY, Watts, JL, Fraser, AG, Kamath, RS, Ahringer, J & Ruvkun, G (2003) Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421, 268272.Google Scholar
Badman, MK & Flier, JS (2005) The gut and energy balance: visceral allies in the obesity wars. Science 307, 19091914.Google Scholar
Bai, Y, Zhang, S, Kim, KS, Lee, JK & Kim, KH (1996) Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. Journal of Biological Chemistry 271, 1393913942.Google Scholar
Baldanzi, G, Filigheddu, N, Cutrupi, S, Catapano, F, Bonissoni, S, Fubini, Aet al. (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. Journal of Cell Biology 159, 10291037.Google Scholar
Bell, CG, Walley, AJ & Froguel, P (2005) The genetics of human obesity. Nature Reviews Genetics 6, 221234.Google Scholar
Beltowski, J (2006a) Role of leptin in blood pressure regulation and arterial hypertension. Journal of Hypertension 24, 789801.Google Scholar
Beltowski, J (2006b) Leptin and atherosclerosis. Atherosclerosis 189, 4760.Google Scholar
Beltowski, J, Wójcicka, G & Borkowska, E (2002) Human leptin stimulates systemic nitric oxide production in the rat. Obesity Research 10, 939946.Google Scholar
Beltowski, J, Wojcicka, G & Jamroz-Wisniewska, A (2006) Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. Life Sciences 79, 6371.Google Scholar
Berg, AH & Scherer, PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 96, 939949.Google Scholar
Berndt, J, Kloting, N, Kralisch, S, Kovacs, P, Fasshauer, M, Schon, MR, Stumvoll, M & Bluher, M (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54, 29112916.Google Scholar
Blüher, M (2005) Transgenic animal models for the study of adipose tissue biology. Best Practice and Research in Clinical Endocrinology and Metabolism 19, 605623.Google Scholar
Bodart, V, Febbraio, M, Demers, A, McNicoll, N, Pohankova, P, Perreault, A, Sejlitz, T, Escher, E, Silverstein, RL, Lamontagne, D & Ong, H (2002) CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research 90, 844849.Google Scholar
Borodina, I & Nielsen, J (2005) From genomes to in silico cells via metabolic networks. Current Opinion in Biotechnology 16, 350355.Google Scholar
Bottini, E & Gloria-Bottini, F (1999) Adenosine deaminase and body mass index in non-insulin-dependent diabetes mellitus. Metabolism 48, 949951.Google Scholar
Bray, GA & York, DA (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiological Reviews 59, 779809.Google Scholar
Buchwald, H, Avidor, Y, Braunwald, E, Jensen, MD, Pories, W, Fahrbach, K & Schoelles, K (2004) Bariatric surgery: a systematic review and meta-analysis. Journal of the American Medical Association 292, 17241737.Google Scholar
Calle, EE, Rodriguez, C, Walker-Thurmond, K & Thun, MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348, 16251638.Google Scholar
Cao, JM, Ong, H & Chen, C (2006) Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends in Endocrinology and Metabolism 17, 1318.Google Scholar
Capozza, F, Combs, TP, Cohen, AW, Cho, YR, Park, SY, Schubert, Wet al. (2005) Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. American Journal of Physiology 288, C1317C1331.Google Scholar
Carella, M, Volinia, S & Gasparini, P (2003) Nanotechnologies and microchips in genetic diseases. Journal of Nephrology 16, 597602.Google Scholar
Chaldakov, GN, Tonchev, AB, Georgieva, Z, Ghenev, PI & Stankulov, IS (2005) Adipobiology of inflammation. Biomedical Reviews 16, 8388.Google Scholar
Chen, M-P, Chung, F-M, Chang, D-M, Tsai, JC-R, Huang, H-F, Shin, S-J & Lee, Y-J (2006) Elevated plasma levels of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 91, 295299.Google Scholar
Clement, K (2005) Genetics of human obesity. Proceedings of the Nutrition Society 64, 133142.Google Scholar
Clément, K, Viguerie, N, Poitou, C, Carette, C, Pelloux, V, Curat, CAet al. (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB Journal 18, 16571669.Google Scholar
Cohen, AW, Combs, TP, Scherer, PE & Lisanti, MP (2003a) Role of caveolin and caveolae in insulin signaling and diabetes. American Journal of Physiology 285, E1151E1160.Google Scholar
Cohen, AW, Hnasko, R, Schubert, W & Lisanti, MP (2004) Role of caveolae and caveolins in health and disease. Physiological Reviews 84, 13411379.Google Scholar
Cohen, AW, Razani, B, Wang, XB, Combs, TP, Williams, TM, Scherer, PE & Lisanti, MP (2003b) Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. American Journal of Physiology 285, C222C235.Google Scholar
Cohen, AW, Schubert, W, Brasaemle, DL, Scherer, PE & Lisanti, MP (2005) Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. Diabetes 54, 679686.Google Scholar
Coleman, DL (1978) Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141148.Google Scholar
Collier, G, Walder, K, De Silva, A, Tenne-Brown, J, Sanigorski, A, Segal, D, Kantham, L & Augert, G (2002) New approaches to gene discovery with animal models of obesity and diabetes. Annals of the New York Academy of Sciences 967, 403413.Google Scholar
Copland, JA, Davies, PJ, Shipley, GL, Wood, CG, Luxon, BA & Urban, RJ (2003) The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside. Recent Progress in Hormone Research 58, 2553.Google Scholar
Correia, ML & Haynes, WG (2004) Leptin, obesity and cardiovascular disease. Current Opinion in Nephrology and Hypertension 13, 215223.Google Scholar
Crookes, PF (2006) Surgical treatment of morbid obesity. Annual Reviews of Medicine 57, 243264.Google Scholar
Cummings, DE & Schwartz, MW (2003) Genetics and pathophysiology of human obesity. Annual Review of Medicine 54, 453471.Google Scholar
Cummings, DE & Shannon, MH (2003) Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? Journal of Clinical Endocrinology and Metabolism 88, 29993002.Google Scholar
Cummings, DE, Weigle, DS, Frayo, RS, Breen, PA, Ma, MK, Dellinger, EP & Purnell, JQ (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine 346, 16231630.Google Scholar
Date, Y, Kojima, M, Hosoda, H, Sawaguchi, A, Mondal, MS, Suganuma, T, Matsukura, S, Kangawa, K & Nakazato, M (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 42554261.Google Scholar
Diéguez, C & Casanueva, FF (2000) Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. European Journal of Endocrinology 142, 413417.Google Scholar
Droit, A, Poirier, GG & Hunter, JM (2005) Experimental and bioinformatic approaches for interrogating protein-protein interactions to determine protein function. Journal of Molecular Endocrinology 34, 263280.Google Scholar
Fantuzzi, G (2005) Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology 115, 911919.Google Scholar
Fantuzzi, G & Faggioni, R (2000) Leptin in the regulation of immunity, inflammation and hematopoiesis. Journal of Leukocyte Biology 68, 437446.Google Scholar
Faraj, M, Havel, PJ, Phélis, S, Blank, D, Sniderman, AD & Cianflone, K (2003) Plasma acylation-stimulating protein, adiponectin, leptin and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. Journal of Clinical Endocrinology and Metabolism 88, 15941602.Google Scholar
Farooqi, IS & O'Rahilly, S (2005) Monogenic obesity in humans. Annual Review of Medicine 56, 443458.Google Scholar
Flier, JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337350.Google Scholar
Fontaine, KR, Redden, DT, Wang, C, Westfall, AO & Allison, DB (2003) Years of life lost due to obesity. Journal of the American Medical Association 289, 187193.Google Scholar
Fortuño, A, Rodríguez, A, Gómez-Ambrosi, J, Muñiz, P, Salvador, J, Díez, J & Frühbeck, G (2002) Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology 143, 35553560.Google Scholar
Frayn, KN, Karpe, F, Fielding, BA, Macdonald, IA & Coppack, SW (2003) Integrative physiology of human adipose tissue. International Journal of Obesity 27, 875888.Google Scholar
Frisch, RE & McArthur, JW (1974) Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science 185, 949951.Google Scholar
Frühbeck, G (1999) Pivotal role of nitric oxide in the control of blood pressure following leptin administration. Diabetes 48, 903908.Google Scholar
Frühbeck, G (2001) A heliocentric view of leptin. Proceedings of the Nutrition Society 60, 301318.Google Scholar
Frühbeck, G (2004a) The adipose tissue as a source of vasoactive factors. Current Medicinal Chemistry – Cardiovascular & Hematological Agents 2, 197208.Google Scholar
Frühbeck, G (2004b) Screening and interventions for obesity in adults. Annals of Internal Medicine 141, 245246.Google Scholar
Frühbeck, G (2005a) Overnutrition. In Clinical Nutrition, pp. 3061. [Gibney, MJ, Elia, M, Ljungqvist, O and Dowsett, J editors]. Oxford: Blackwell Publishing.Google Scholar
Frühbeck, G (2005b) Aquaporin enters the picture. Nature 438, 436437.Google Scholar
Frühbeck, G (2005c) Does a NEAT difference in energy expenditure lead to obesity? Lancet 366, 615616.Google Scholar
Frühbeck, G (2006) Intracellular signalling pathways activated by leptin. Biochemical Journal 393, 720.Google Scholar
Frühbeck, G, Aguado, M & Martínez, JA (1997) In vitro lipolytic effect of leptin on mouse adipocytes: evidence for a possible autocrine-paracrine role of leptin. Biochemical and Biophysical Research Communications 240, 590594.Google Scholar
Frühbeck, G, Aguado, M, Gómez-Ambrosi, J & Martínez, JA (1998) Lipolytic effect of in vivo leptin administration on adipocytes of lean and ob/ob mice, but not db/db mice. Biochemical and Biophysical Research Communications 240, 590594.Google Scholar
Frühbeck, G, Catalán, V, Gómez-Ambrosi, J & Rodríguez, A (2006) Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends in Pharmacological Sciences 27, 345347.Google Scholar
Frühbeck, G, Diez-Caballero, A, Gil, MJ, Montero, I, Gómez-Ambrosi, J, Salvador, J & Cienfuegos, JA (2004a) The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obesity Surgery 14, 606612.Google Scholar
Frühbeck, G, Diez-Caballero, A & Gil, MJ (2004b) Fundus functionality and ghrelin concentrations after bariatric surgery. New England Journal of Medicine 350, 308309.Google Scholar
Frühbeck, G, Diez-Caballero, A, Gómez-Ambrosi, J, Cienfuegos, JA & Salvador, J (2003) Doctors underestimate obesity. British Medical Journal 326, 102103.Google Scholar
Frühbeck, G, Diez-Caballero, A, Gómez-Ambrosi, J, Gil, MJ, Monreal, I, Salvador, J & Cienfuegos, JA (2002) Disruption of the leptin-insulin relationship in obese men 24 hours after laparoscopic adjustable silicone gastric banding. Obesity Surgery 12, 366371.Google Scholar
Frühbeck, G & Gómez-Ambrosi, J (2001a) Rationale for the existence of additional adipostatic hormones. FASEB Journal 15, 19962006.Google Scholar
Frühbeck, G & Gómez-Ambrosi, J (2001b) Modulation of the leptin-induced white adipose tissue lipolysis by nitric oxide. Cellular Signalling 13, 827833.Google Scholar
Frühbeck, G & Gómez-Ambrosi, J (2003) Control of body weight: a physiologic and transgenic perspective. Diabetologia 46, 143172.Google Scholar
Frühbeck, G & Gómez-Ambrosi, J (2005) Adipose tissue. In Encyclopedia of Human Nutrition, vol. 1, 2nd ed., pp. 114 [Caballero, B, Allen, L and Prentice, Aeditors]. Oxford: Elsevier Ltd.Google Scholar
Frühbeck, G, Gómez-Ambrosi, J, Muruzábal, FJ & Burrell, MA (2001a) The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology 280, E827E847.Google Scholar
Frühbeck, G, Gómez-Ambrosi, J & Salvador, J (2001b) Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB Journal 15, 333340.Google Scholar
Frühbeck, G, Rotellar, F, Hernández-Lizoain, JL, Gil, MJ, Gómez-Ambrosi, J, Salvador, J & Cienfuegos, JA (2004c) Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obesity Surgery 14, 12081215.Google Scholar
Frühbeck, G & Salvador, J (2004) Role of adipocytokines in metabolism and disease. Nutrition Research 24, 803826.Google Scholar
Fry, J & Finley, W (2005) The prevalence and costs of obesity in the EU. Proceedings of the Nutrition Society 64, 359362.Google Scholar
Fukuhara, A, Matsuda, M, Nishizawa, M, Segawa, K, Tanaka, M, Kishimoto, Ket al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426430.Google Scholar
Galuska, DA, Will, JC, Serdula, MK & Ford, ES (1999) Are health care professionals advising obese patiens to lose weight? Journal of the American Medical Association 282, 15761578.Google Scholar
Ghigo, E, Broglio, F, Arvat, E, Maccario, M, Papotti, M & Muccioli, G (2005) Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clinical Endocrinology 62, 117.Google Scholar
Gnanapavan, S, Kola, B, Bustin, SA, Morris, DG, McGee, P, Fairclough, P, Bhattacharya, S, Carpenter, R, Grossman, AB & Korbonits, M (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. Journal of Clinical Endocrinology and Metabolism 87, 29882991.Google Scholar
Gómez-Ambrosi, J, Becerril, S, Oroz, P, Zabalza, S, Rodríguez, A, Muruzábal, FJ, Archanco, M, Gil, MJ, Burrell, MA & Frühbeck, G (2004a) Reduced adipose tissue mass and hypoleptinemia in iNOS deficient mice: effect of LPS on plasma leptin and adiponectin concentrations. FEBS Letters 577, 351356.Google Scholar
Gómez-Ambrosi, J, Catalán, V, Diez-Caballero, A, Martínez-Cruz, A, Gil, MJ, García-Foncillas, J, Cienfuegos, JA, Salvador, J, Mato, JM & Frühbeck, G (2004b) Gene expression profile of omental adipose tissue in human obesity. FASEB Journal 18, 215218.Google Scholar
Gómez-Ambrosi, J & Frühbeck, G (2001) Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Annals of Internal Medicine 135, 306307.Google Scholar
Gómez-Ambrosi, J & Frühbeck, G (2005a) Evidence for the involvement of resistin in inflammation and cardiovascular disease. Current Diabetes Reviews 1, 227234.Google Scholar
Gómez-Ambrosi, J & Frühbeck, G (2005b) Resistin: a promising therapeutic target for the management of type 2 diabetes mellitus? Drug Design Reviews – Online 2, 112.Google Scholar
Gómez-Ambrosi, J, Salvador, J, Páramo, JA, Orbe, J, de Irala, J, Diez-Caballero, A, Gil, MJ, Cienfuegos, JA & Frühbeck, G (2002) Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clinical Biochemistry 35, 315320.Google Scholar
Gómez-Ambrosi, J, Salvador, J, Rotellar, F, Silva, C, Catalán, V, Rodríguez, A, Gil, MJ & Frühbeck, G (2006a) Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obesity Surgery 15, 262269.Google Scholar
Gómez-Ambrosi, J, Salvador, J, Silva, C, Pastor, C, Rotellar, F, Gil, MJ, Cienfuegos, JA & Frühbeck, G (2006b) Increased cardiovascular risk markers in obesity are associated with body adiposity: role of leptin. Thrombosis and Haemostasis 95, 991996.Google Scholar
Gómez-Ambrosi, J, Salvador, J, Silva, C, Rotellar, F, Gil, MJ, Cienfuegos, JA & Frühbeck, G (2005) Leptin therapy does not affect inflammatory markers. Journal of Clinical Endocrinology and Metabolism 90, 3802.Google Scholar
Greenberg, AS, Taylor, SI & Londos, C (1987) Presence of a functional inhibitory GTP-binding regulatory component, Gi, linked to adenylate cyclase in adipocytes of ob/ob mice. Journal of Biological Chemistry 262, 45644568.Google Scholar
Gregg, EW, Cheng, YJ, Cadwell, BL, Imperatore, G, Williams, DE, Flegal, KM, Narayan, KMV & Williamson, DF (2005). Secular trends in cardiovascular risk factors according to body mass index in US adults. Journal of the American Medical Association 293, 18681874.Google Scholar
Grunweller, A & Hartmann, RK (2005) RNA interference as a gene-specific approach for molecular medicine. Current Medical Chemistry 12, 31433161.Google Scholar
Hansen, EN, Torquati, A & Abumrad, NN (2006) Results of bariatric surgery. Annual Reviews of Nutrition 26, 481511.Google Scholar
Hansson, GK (2005) Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 352, 16851695.Google Scholar
Hanush-Enserer, U, Brabant, G & Roden, M (2003). Ghrelin concentrations in morbidly obese patients after adjustable gastric banding. New England Journal of Medicine 348, 21592160.Google Scholar
Hara-Chikuma, M, Sohara, E, Rai, T, Ikawa, M, Okabe, M, Sasaki, S, Uchida, S & Verkman, AS (2005) Progressive adipocyte hypertrophy in aquaporin-7-deficient mice. Journal of Biological Chemistry 280, 1549315496.Google Scholar
Hara-Chikuma, M & Verkman, AS (2006) Physiological roles of glycerol-transporting aquaporins: the aquaglyceroporins. Cellular and Molecular Life Sciences 63, 13861392.Google Scholar
Härle, P & Straub, RH (2006) Leptin is a link between adipose tissue and inflammation. Annals of the New York Academy of Sciences 1069, 454462.Google Scholar
Hauner, H (2005) Secretory factors from human adipose tissue and their functional role. Proceedings of the Nutrition Society 64, 163169.Google Scholar
Hetherington, AW & Ranson, SW (1940) Hypothalamic lesions and adiposity in the rat. The Anatomical Record 78, 149172.Google Scholar
Hibuse, T, Maeda, N, Funahashi, T, Yamamoto, K, Nagasawa, A, Mizunoya, Wet al. (2005) Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase. Proceedings of the National Academy of Sciences USA 102, 1099310998.Google Scholar
Holcomb, IN, Kabakoff, RC, Chan, B, Baker, TW, Gurney, A, Henzel, Wet al. (2000) FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO Journal 19, 40464055.Google Scholar
Honnor, RC, Dhillon, GS & Londos, C (1985a) cAMPdependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation, and predictability in behavior. Journal of Biological Chemistry 260, 1512215129.Google Scholar
Honnor, RC, Dhillon, GS & Londos, C (1985b) cAMPdependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators. Journal of Biological Chemistry 260, 1513015138.Google Scholar
Hörig, H, Marincola, E & Marincola, FM (2005) Obstacles and opportunities in translational research. Nature Medicine 11, 705708.Google Scholar
Horvath, TL (2005) The hardship of obesity: a soft-wired hypothalamus. Nature Neuroscience 8, 561565.Google Scholar
Inui, A, Asakawa, A, Bowers, CY, Mantovani, G, Laviano, A, Meguid, MM & Fujimiya, M (2004) Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB Journal 18, 439456.Google Scholar
Ishibashi, K, Yamauchi, K, Kageyama, Y, Saito-Ohara, F, Ikeuchi, T, Marumo, F & Sasaki, S (1998) Molecular characterization of human Aquaporin-7 gene and its chromosomal mapping. Biochimica et Biophysica Acta 1399, 6266.Google Scholar
Ishikawa, Y, Otsu, K & Oshikawa, J (2005) Caveolin; different roles for insulin signal? Cellular Signalling 17, 11751182.Google Scholar
Jebb, SA, Siervo, M, Frühbeck, G, Murgatroyd, PR, Goldberg, G & Prentice, AM (2006) Variability of appetite control mechanisms in response to 9 weeks of progressive overfeeding in humans. International Journal of Obesity 30, 11601162.Google Scholar
Kadowaki, T & Yamauchi, T (2005) Adiponectin and adiponectin receptors. Endocrine Reviews 26, 439451.Google Scholar
Kawanami, D, Maemura, K, Takeda, N, Harada, T, Nojiri, T, Imai, Y, Manabe, I, Utsunomiya, K & Nagai, R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochemical and Biophysical Research Communications 314, 415419.Google Scholar
Kawczynska-Drozdz, A, Olszanecki, R, Jawien, J, Brzozowski, T, Pawlik, WW, Korbut, R & Guzik, TJ (2006) Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. American Journal of Hypertension 19, 764767.Google Scholar
Kimura, K, Tsuda, K, Baba, A, Kawabe, T, Boh-oka, S, Ibata, M, Moriwaki, C, Hano, T & Nishio, I (2000) Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochemical and Biophysical Research Communications 273, 745749.Google Scholar
King, LS, Kozono, D & Agre, P (2004) From structure to disease: the evolving tale of aquaporin biology. Nature Reviews in Molecular Cell Biology 5, 687698.Google Scholar
Kishida, K, Shimomura, I, Kondo, H, Kuriyama, H, Makino, Y, Nishizawa, Het al. (2001) Genomic structure and insulin-mediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel. Journal of Biological Chemistry 276, 3625136260.Google Scholar
Klein, J, Perwitz, N, Kraus, D & Fasshauer, M (2006) Adipose tissue as source and target for novel therapies. Trends in Endocrinology and Metabolism 17, 2632.Google Scholar
Koerner, A, Kratzsch, J & Kiess, W (2005) Adipocytokines: leptin – the classical, resistin – the controversial, adiponectin – the promising, and more to come. Best Practice and Research in Clinical Endocrinology and Metabolism 19, 525546.Google Scholar
Kojima, M, Hosoda, H, Date, Y, Nakazato, M, Matsuo, H & Kangawa, K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656660.Google Scholar
Kondo, H, Shimomura, I, Kishida, K, Kuriyama, H, Makino, Y, Nishizawa, Het al. (2002) Human aquaporin adipose (AQPap) gene. Genomic structure, promoter analysis and functional mutation. European Journal of Biochemistry 269, 18141826.Google Scholar
Kopelman, PG (2000) Obesity as a medical problem. Nature 404, 635643.Google Scholar
Kralisch, S, Klein, J, Lossner, U, Bluher, M, Paschke, R, Stumvoll, M & Fasshauer, M (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. American Journal of Physiology 289, E586E590.Google Scholar
Krebs, JD, Evans, S, Cooney, L, Mishra, GD, Frühbeck, G, Finer, N & Jebb, SA (2002) Changes in risk factors for cardiovascular disease with body fat loss in obese women. Diabetes Obesity and Metabolism 4, 379387.Google Scholar
Kuriyama, H, Kawamoto, S, Ishida, N, Ohno, I, Mita, S, Matsuzawa, Y, Nishizawa, H, Matsubara, K & Okubo, K (1997) Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochemical and Biophysical Research Communication 241, 5358.Google Scholar
Kuriyama, H, Shimomura, I, Kishida, K, Kondo, H, Furuyama, N, Nishizawa, Het al. (2002) Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 51, 29152921.Google Scholar
LaNoue, KF & Martin, LF (1994) Abnormal A1 adenosine receptor function in genetic obesity. FASEB Journal 8, 7280.Google Scholar
Lau, DC, Dhillon, B, Yan, H, Szmitko, PE & Verma, S (2005) Adipokines: molecular links between obesity and atherosclerosis. American Journal of Physiology 288, H20312041.Google Scholar
Le Lay, S & Kurzchalia, TV (2005) Getting rid of caveolins: phenotypes of caveolin-deficient animals Biochemica et Biophysica Acta 1746, 322333.Google Scholar
Lehrke, M, Reilly, MP, Millington, SC, Iqbal, N, Rader, DJ & Lazar, MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PloS Medicine 1, 161168.Google Scholar
Lembo, G, Vecchione, C, Fratta, L, Marino, G, Trimarco, V, d'Amati, G & Trimarco, B (2000) Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 49, 293297.Google Scholar
MacDougald, OA & Burant, CF (2005) Obesity and metabolic perturbations after loss of aquaporin 7, the adipose tissue transporter. Proceedings of the National Academy of Sciences USA 102, 1075910760.Google Scholar
Maeda, N, Funahashi, T, Nagasawa, A, Kishida, K, Kuriyama, H, Nakamura, T, Kihara, S, Shimomura, I & Matsuzawa, Y (2004) Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proceedings of the National Academy of Sciences USA 101, 1780117806.Google Scholar
Martin, LF, Klim, CM, Vannucci, SJ, Dixon, LB, Landis, JR & LaNoue, KF (1990) Alterations in adipocyte adenylate cyclase activity in morbidly obese and formerly morbidly obese humans. Surgery 108, 228235.Google Scholar
Matsuzawa, Y (2005) White adipose tissue and cardiovascular disease. Best Practice and Research in Clinical Endocrinology and Metabolism 19, 637647.Google Scholar
Matsuzawa, Y (2006) Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine 3, 3542.Google Scholar
Middleton, FA, Ramos, EJ, Xu, Y, Diab, H, Zhao, X, Das, UN & Meguid, M (2004) Application of genomic technologies: DNA microarrays and metabolic profiling of obesity in the hypothalamus and in subcutaneous fat. Nutrition 20, 1425.Google Scholar
Miyazawa-Hoshimoto, S, Takahashi, K, Bujo, H, Hashimoto, N & Saito, Y (2003) Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 46, 14831488.Google Scholar
Mobasheri, A, Airley, R, Foster, CS, Schulze-Tanzil, G & Shakibaei, M (2004) Post-genomic applications of tissue microarrays: basic research, prognostic oncology, clinical genomics and drug discovery. Histology and Histopathology 19, 325355.Google Scholar
Mokdad, AH, Ford, ES, Bowman, BA, Dietz, WH, Vinicor, F, Bales, VS & Marks, JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 289, 7679.Google Scholar
Montecucco, F, Bianchi, G, Gnerre, P, Bertolotto, M, Dallegri, F & Ottonello, L (2006) Induction of neutrophil chemotaxis by leptin: crucial role for p38 and Src kinases. Annals of the New York Academy of Sciences 1069, 463471.Google Scholar
Morinigo, R, Casamitjana, R, Moize, V, Lacy, AM, Delgado, S, Gomis, R & Vidal, J (2004) Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obesity Research 12, 11081116.Google Scholar
Müller, M & Kersten, S (2003) Nutrigenomics: goals and strategies. Nature Reviews Genetics 4, 315322.Google Scholar
Nadler, ST & Attie, AD (2001) Please pass the chips: genomic insights into obesity and diabetes. Journal of Nutrition 131, 20782081.Google Scholar
National Audit Office (2001) Tackling Obesity in England. Report by the Comptroller and Auditor General HC 220 Session 2000–2001: 15 February 2001. http://www.nao.gov.uk/publications/nao_reports/00-01/0001220.pdfGoogle Scholar
O'Brien, PE, Dixon, JB, Laurie, C, Skinner, S, Proietto, J, McNeil, J, Strauss, B, Marks, S, Schachter, L, Chapman, L & Anderson, M (2006) Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Annals of Internal Medicine 144, 625633.Google Scholar
Ogden, CL, Carroll, MD, Curtin, LR, McDowell, MA, Tabak, CJ & Flegal, KM (2006) Prevalence of overweight and obesity in the United States, 1999–2004. Journal of the American Medical Association 295, 15491555.Google Scholar
Olshansky, SJ, Passaro, DJ, Hershow, RC, Layden, J, Carnes, BA, Brody, J, Hayflick, L, Butler, RN, Allison, DB & Ludwig, DS (2005) A potential decline in life expectancy in the United States in the 21st century. New England Journal of Medicine 352, 11381145.Google Scholar
Oommen, AM, Griffin, JB, Sarath, G & Zempleni, J (2005) Roles for nutrients in epigenetic events. Journal of Nutritional Biochemistry 16, 7477.Google Scholar
Oshikawa, J, Otsu, K, Toya, Y, Tsunematsu, T, Hankins, R, Kawabe, J, Minamisawa, S, Umemura, S, Hagiwara, Y & Ishikawa, Y (2004) Insulin resistance in skeletal muscles of caveolin-3-null mice. Proceedings of the National Academy of Sciences USA 101, 1267012675.Google Scholar
Ouchi, N, Kihara, S, Arita, Y, Okamoto, Y, Maeda, N, Kuriyama, Het al. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102, 12961301.Google Scholar
Ouchi, N, Kihara, S, Funahashi, T, Nakamura, T, Nishida, M, Kumada, Met al. (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107, 671674.Google Scholar
Papotti, M, Ghe, C, Cassoni, P, Catapano, F, Deghenghi, R, Ghigo, E & Muccioli, G (2000) Growth hormone secretagogue binding sites in peripheral human tissues. Journal of Clinical Endocrinology and Metabolism 85, 38033807.Google Scholar
Parton, RG, Hanzal-Bayer, M & Hancock, JF (2006) Biogenesis of caveolae: a structural model for caveolin-induced domain formation. Journal of Cell Science 119, 787796.Google Scholar
Parton, RG, Joggerst, B & Simons, K (1994) Regulated internalization of caveolae. Journal of Cell Biology 127, 11991215.Google Scholar
Peelman, F, Couturier, C, Dam, J, Zabeau, L, Tavernier, J & Jockers, R (2006) Techniques: new pharmacological perspectives for the leptin receptor. Trends in Pharmacological Sciences 27, 218225.Google Scholar
Permana, PA, Menge, C & Reaven, PD (2006) Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochemical and Biophysical Research Communication 341, 507514.Google Scholar
Pischon, T, Girman, CJ, Hotamisligil, GS, Rifai, N, Hu, FB & Rimm, EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. Journal of the American Medical Association 291, 17301737.Google Scholar
Rankinen, T, Zuberi, A, Chagnon, YC, Weisnagel, Argyropoulos G, Walts, B, Pérusse, L & Bouchard, C (2006) The human obesity gene map: the 2005 update. Obesity 14, 529544.Google Scholar
Razani, B, Combs, TP, Wang, XB, Frank, PG, Park, DS, Russell, RG, Li, M, Tang, B, Jelicks, LA, Scherer, PE & Lisanti, MP (2002) Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. Journal of Biological Chemistry 277, 86358647.Google Scholar
Rice, AM, Fain, JN & Rivkees, SA (2000) A1 adenosine receptor activation increases adipocyte leptin secretion. Endocrinology 141, 14421445.Google Scholar
Rodríguez, A, Frühbeck, G, Gómez-Ambrosi, J, Catalán, V, Sáinz, N, Díez, J, Zalba, G & Fortuño, A (2006) The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. Journal of Hypertension (In the Press).Google Scholar
Rothberg, KG, Heuser, JE, Donzell, WC, Ying, Y, Glenney, JR & Anderson, RGW (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68, 673682.Google Scholar
Ruden, DM, De Luca, M, Garfinkel, MD, Bynum, KL & Lu, X (2005) Drosophila nutrigenomics can provide clues to human gene-nutrient interactions. Annual Review of Nutrition 25, 499522.Google Scholar
Rybin, VO, Grabham, PW, Elouardighi, H & Steinberg, SF (2003) Caveolae-associated proteins in cardiomyocytes: caveolin-2 expression and interactions with caveolin-3. American Journal of Physiology 285, H325H332.Google Scholar
Sakata, I, Nakamura, K, Yamazaki, M, Matsubara, M, Hayashi, Y, Kangawa, K & Sakai, T (2002) Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23, 531536.Google Scholar
Scherer, PE, Lewis, RY, Volonte, D, Engelman, JA, Galbiati, F, Couet, J, Kohtz, DS, van Donselaar, E, Peters, P & Lisanti, MP (1997) Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 colocalize and form a stable hetero-oligomieric complex in vivo. Journal of Cell Biology 272, 2933729346.Google Scholar
Sethi, JK & Vidal-Puig, A (2005) Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends in Molecular Medicine 11, 344347.Google Scholar
Shankar, P, Manjunath, N & Lieberman, J (2005) The prospect of silencing disease using RNA interference. Journal of the American Medical Association 293, 13671373.Google Scholar
Shimizu, Y, Nagaya, N, Teranishi, Y, Imazu, M, Yamamoto, H, Shokawa, T, Kangawa, K, Kohno, N & Yoshizumi, M (2003) Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochemical and Biophysical Research Communications 310, 830835.Google Scholar
Sjöholm, K & Nyström, T (2005) Endothelial inflammation in insulin resistance. Lancet 365, 610612.Google Scholar
Sjöholm, K, Palming, J, Olofsson, LE, Gummesson, A, Svensson, PA, Lystig, TC, Jennische, E, Brandberg, J, Torgerson, JS, Carlsson, B & Carlsson, LM (2005) A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid. Journal of Clinical Endocrinology and Metabolism 90, 22332239.Google Scholar
Skilton, MR, Nakhla, S, Sieveking, DP, Caterson, ID & Celermajer, DS (2005) Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clinical and Experimental Pharmacology and Physiology 32, 839844.Google Scholar
Song, KS, Scherer, PE, Tang, ZL, Okamoto, T, Li, S, Chu, C, Chafel, M, Chu, C, Kohtz, DS & Lisanti, MP (1996) Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. Journal of Biological Chemistry 271, 1516015165.Google Scholar
Stan, RV (2005) Structure of caveolae. Biochemica et Biophysica Acta 1746, 334348.Google Scholar
Steinbrook, R (2004) Surgery for severe obesity. New England Journal of Medicine 350, 10751079.Google Scholar
Steppan, CM, Bailey, ST, Bhat, S, Brown, EJ, Banerjee, RR, Wright, CM, Patel, HR, Ahima, RS & Lazar, MA (2001) Nature 409, 307312.Google Scholar
Steppan, CM & Lazar, MA (2004) The current biology of resistin. Journal of Internal Medicine 255, 439447.Google Scholar
Tang, ZL, Scherer, PE, Okamoto, T, Song, K, Chu, C, Kohtz, DS, Nishimoto, I, Lodish, HF & Lisanti, MP (1996) Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. Journal of Biological Chemistry 271, 22552261.Google Scholar
Tomasetto, C, Karam, SM, Ribieras, Set al. (2000) Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 119, 395405.Google Scholar
Trayhurn, P (2005a) Obesity – what role now for nutritional science? British Journal of Nutrition 93, 12.Google Scholar
Trayhurn, P (2005b) The biology of obesity. Proceedings of the Nutrition Society 64, 3138.Google Scholar
Trayhurn, P & Beattie, JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proceedings of the Nutrition Society 60, 329339.Google Scholar
Trayhurn, P & Wood, IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition 92, 347355.Google Scholar
Urieli-Shoval, S, Linke, RP & Matzner, Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Current Opinion in Hematology 7, 6469.Google Scholar
Vaidya, V (2006) Psychosocial aspects of obesity. Advances in Psychosomatic Medicine 27, 7385.Google Scholar
Vannucci, SJ, Klim, CM, Martin, LF & LaNoue, KF (1989) A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats. American Journal of Physiology 257, E871E878.Google Scholar
Vecchione, C, Maffei, A, Colella, S, Aretini, A, Poulet, R, Frati, G, Gentile, MT, Fratta, L, Trimarco, V, Trimarco, B & Lembo, G (2002) Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51, 168173.Google Scholar
Verkman, AS (2005) More than just water channels: unexpected cellular roles of aquaporins. Journal of Cellular Science 118, 32253232.Google Scholar
Verma, S, Li, SH, Wang, CH, Fedak, PW, Li, RK, Weisel, RD & Mickle, DA (2003) Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108, 736740.Google Scholar
Viguerie, N, Poitou, C, Cancello, R, Stich, V, Clement, K & Langin, D (2005) Transcriptomics applied to obesity and caloric restriction. Biochimie 87, 117123.Google Scholar
Wang, M-Y, Lee, Y & Unger, RH (1998) Novel form of lipolysis induced by leptin. Journal of Biological Chemistry 274, 1754117544.Google Scholar
Wellen, KE & Hotamisligil, GS (2003) Obesity-induced inflammatory changes in adipose tissue. Journal of Clinical Investigation 112, 17851788.Google Scholar
Wiley, KE & Davenport, AP (2002) Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. British Journal of Pharmacology 136, 11461152.Google Scholar
Winters, B, Mo, Z, Brooks-Asplund, E, Kim, S, Shoukas, A, Li, D, Nyhan, D & Berkowitz, DE (2000) Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep ob) mice. Journal of Applied Physiology 89, 23822390.Google Scholar
Wintour, EM & Henry, BA (2006) Glycerol transport: an additional target for obesity therapy? Trends in Endocrinology and Metabolism 17, 7778.Google Scholar
Xydakis, AM, Case, CC, Jones, PH, Hoogeveen, RC, Liu, M-Y, O'Brian, Smith E, Nelson, KW & Ballantyne, CM (2004) Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. Journal of Clinical Endocrinology and Metabolism 89, 26972703.Google Scholar
Yamamoto, M, Toya, Y, Schwencke, C, Lisanti, MP, Myers, MG Jr & Ishikawa, Y (1998) Caveolin is an activator of insulin receptor signaling. Journal of Biological Chemistry 273, 26962–26968.Google Scholar
Yamauchi, T, Kamon, J, Ito, Y, Tsuchida, A, Yokomizo, T, Kita, Set al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762769.Google Scholar
Yu, YH & Ginsberg, HN (2005) Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circulation Research 96, 10421052.Google Scholar
Zerhouni, EA (2005) Translational and clinical science – time for a new vision. New England Journal of Medicine 353, 16211623.Google Scholar
Figure 0

Fig. 1. Schematic representation of the selected research lines in obesity. (a), an image of a microarray; (b), a protein spectrum; VSMC, vascular smooth muscle cells; EC, endothelial cells.

Figure 1

Fig. 2. Active cross talk between the numerous mediators secreted by the different cellular components of adipose tissue, which are enhanced in states of obesity, accompanied by recruitment of macrophages. Adipocytes and other cell types secrete inflammatory cytokines and immune factors exerting relevant autocrine, paracrine and endocrine influences. EC, endothelial cell; VSMC, vascular smooth muscle cell; MCP-1, monocyte chemoattractant protein-1; VEGF, vascular endothelial growth factor; C3, complement factor.

Figure 2

Fig. 3. Lipolysis under nitric oxide synthase (NOS) inhibition and acute ganglionic blockade. Wistar rats under pharmacological pretreatment consisting of intravenous administration of vehicle (saline (9 g sodium chloride/l); control group), NOS inhibition (Nωnitro-l-arginine methyl ester (L-NAME); 30 mg/kg) or acute ganglionic blockade (chlorisondamine; 30 mg/kg) were further injected with either saline (□) or leptin (100 mg/kg; ////) to study the effect on basal lipolysis of fat cells. The lipolytic activity was measured as the amount of glycerol released by isolated adipocytes after 1 h. Results are expressed as the percentage of basal lipolysis of fat cells from saline-treated control animals and are mean values with their standard errors represented by vertical bars for eight animals per group (lipolytic experiments were performed in duplicate). Mean values were significantly different from those for the saline-treated animals within the same pharmacological pretreatment group: **P<0·01, ***P<0·001. Mean values were significantly different from those for the control leptin-treated animals: †P<0·05. Statistical analyses were performed using ANOVA and post hoc pair-wise comparisons.

Figure 3

Fig. 4. Diagram of the site of action of diverse pharmacological agents at different levels of the lipolytic pathway. FSK, forskolin; AC, adenylate cyclase; Bt2-cAMP, dibutyryl-cAMP; HSL, hormone-sensitive lipase; PTX, pertussis toxin; Gi, inhibitory G-coupled protein; PKA, protein kinase A; CPA, N6-cyclopentyladenosine; ADA, adenosine deaminase; Adenos, adenosine; A1, adenosine receptor; PDE, phosphodiesterase E; P, phosphate; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; IBMX, isobutylmethylxanthine; , inhibitor; +, promoter.

Figure 4

Fig. 5. Schematic representation of the nutritional and neuroendocrine factors regulating aquaporin-7 (AQP7) expression in adipocytes.

Figure 5

Fig. 6. Location of caveolin in the plasma membrane invaginations (or caveolae) and potential underlying mechanisms that lead ultimately to insulin resistance via insulin receptor (Ins-R) signalling defects.

Figure 6

Fig. 7. Diagram illustrating the nitric oxide-dependent intracellular pathways activated by leptin in arteries participating in blood pressure regulation. OB-R, leptin receptor; PI3K, phosphoinositol-3 kinase; JAK, Janus kinase; STAT, signal transduction and activator of transcription; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; Ang, angiotensin; ACE, angiotensin-converting enzyme; AT1-R, angiotensin receptor type 1; [Ca2+]i, cystolic calcium; , increase.

Figure 7

Fig. 8. Scatter diagram showing the highly significant positive correlation (n 553; r 0·144; P<0·001) between the circulating concentrations of log leptin and log C-reactive protein (CRP). (●), Men; (△), women.

Figure 8

Fig. 9. Clinical, patient-oriented and basic research merge into a single continuous bidirectional spectrum synergistically opening up new areas of knowledge and successful implementation.

Figure 9

Fig. 10. Trying to fit the numerous pieces of the complex puzzle of obesity. SHIP2, type-II SH2-domain-containing inositol 5′-phosphatase; FABP, fatty acid-binding protein; SREBP-1, sterol regulatory element-binding protein 1; Sirt 1, sirtuin 1; elF4E, eukaryotic initiation factor 4E; FOX, Forkhead box protein (a transcription factor); carboxypep E, carboxypeptidase E; lysophospholip D, lysophospholipid D; TGF, transforming growth factor; HSL, hormone-sensitive lipase; VEGF, vascular endothelial growth factor; HIF-1, hypoxia-inducible factor-1; CGRP, calcitonin gene-related peptide; SAA, serum amyloid A.